357-70-0 | Galanthamine

Packsize	Purity	Availability	Price	Discounted Price
5mg	≥98%	in stock	$62.00	$44.00
10mg	≥98%	in stock	$92.00	$64.00
25mg	≥98%	in stock	$151.00	$106.00
100mg	≥98 %	in stock	$225.00	$158.00
500mg	≥98 %	in stock	$839.00	$587.00
1g	≥98 %	in stock	$1,467.00	$1,027.00

Description

• Catalog Number: AB51148
• Chemical Name: Galanthamine
• CAS Number: 357-70-0
• Molecular Formula: C17H21NO3
• Molecular Weight: 287.3535
• MDL Number: MFCD00867189
• SMILES: COc1ccc2c3c1O[C@@H]1[C@@]3(CCN(C2)C)C=C[C@@H](C1)O
• NSC Number: 759861

Computed Properties

• Complexity: 440
• Covalently-Bonded Unit Count: 1
• Defined Atom Stereocenter Count: 3
• Heavy Atom Count: 21
• Hydrogen Bond Acceptor Count: 4
• Hydrogen Bond Donor Count: 1
• Rotatable Bond Count: 1
• XLogP3: 1.8

Literature

• Can nonalcoholic beer, silicon and hops reduce the brain damage and behavioral changes induced by aluminum nitrate in young male Wistar rats?

  Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association 20180801

• Canagliflozin prevents scopolamine-induced memory impairment in rats: Comparison with galantamine hydrobromide action.

  Chemico-biological interactions 20171101

• Zebrafish is a predictive model for identifying compounds that protect against brain toxicity in severe acute organophosphorus intoxication.

  Archives of toxicology 20170101

• Design and synthesis of N-substituted-2-hydroxyiminoacetamides and interactions with cholinesterases.

  Chemico-biological interactions 20161125

• Cardanol-derived AChE inhibitors: Towards the development of dual binding derivatives for Alzheimer's disease.

  European journal of medicinal chemistry 20160127

• Zebrafish biosensor for toxicant induced muscle hyperactivity.

  Scientific reports 20160101

• Selective activation of α7 nicotinic acetylcholine receptor by PHA-543613 improves Aβ25-35-mediated cognitive deficits in mice.

  Neuroscience 20150709

• Effect of reversible ligands on oxime-induced reactivation of sarin- and cyclosarin-inhibited human acetylcholinesterase.

  Toxicology letters 20150203

• Cloning and characterization of a norbelladine 4'-O-methyltransferase involved in the biosynthesis of the Alzheimer's drug galanthamine in Narcissus sp. aff. pseudonarcissus.

  PloS one 20140101

• Inhibition of human carboxylesterases hCE1 and hiCE by cholinesterase inhibitors.

  Chemico-biological interactions 20130325

• Cognitive enhancement as a treatment for drug addictions.

  Neuropharmacology 20130101

• Simultaneous quantification of Amaryllidaceae alkaloids from Zephyranthes grandiflora by UPLC-DAD/ESI-MS/MS.

  Journal of pharmaceutical and biomedical analysis 20121201

• Design, synthesis, and bioevaluation of benzamides: novel acetylcholinesterase inhibitors with multi-functions on butylcholinesterase, Aβ aggregation, and β-secretase.

  Bioorganic & medicinal chemistry 20121115

• Selectivity, cocrystal structures, and neuroprotective properties of leucettines, a family of protein kinase inhibitors derived from the marine sponge alkaloid leucettamine B.

  Journal of medicinal chemistry 20121108

• Food-drug interactions: effect of capsaicin on the pharmacokinetics of galantamine in rats.

  Xenobiotica; the fate of foreign compounds in biological systems 20121101

• In-vitro evaluation of the P-glycoprotein interactions of a series of potentially CNS-active Amaryllidaceae alkaloids.

  The Journal of pharmacy and pharmacology 20121101

• Investigation of formulation factors affecting in vitro and in vivo characteristics of a galantamine transdermal system.

  International journal of pharmaceutics 20121015

• A novel class of selective acetylcholinesterase inhibitors: synthesis and evaluation of (E)-2-(benzo[d]thiazol-2-yl)-3-heteroarylacrylonitriles.

  Molecules (Basel, Switzerland) 20121015

• The novel adenosine A(2A) antagonist prodrug MSX-4 is effective in animal models related to motivational and motor functions.

  Pharmacology, biochemistry, and behavior 20121001

• Quantification of galantamine in human plasma by validated liquid chromatography-tandem mass spectrometry using glimepride as an internal standard: application to bioavailability studies in 32 healthy Korean subjects.

  Journal of chromatographic science 20121001

• Apoptosis-inducing effects of distichamine and narciprimine, rare alkaloids of the plant family Amaryllidaceae.

  Bioorganic & medicinal chemistry letters 20121001

• Mapping of the interaction sites of galanthamine: a quantitative analysis through pairwise potentials and quantum chemistry.

  Journal of computer-aided molecular design 20121001

• Galantamine, an acetylcholinesterase inhibitor and positive allosteric modulator of nicotinic acetylcholine receptors, attenuates nicotine taking and seeking in rats.

  Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 20120901

• Effects of fungicides on galanthamine and metabolite profiles in Narcissus bulbs.

  Plant physiology and biochemistry : PPB 20120901

• High-performance liquid chromatography with fast-scanning fluorescence detection and multivariate curve resolution for the efficient determination of galantamine and its main metabolites in serum.

  Analytica chimica acta 20120831

• Pharmacological properties and protein binding capacity of phenolic extracts of some Venda medicinal plants used against cough and fever.

  Journal of ethnopharmacology 20120830

• Acetylcholinesterase-inhibiting activity of salicylanilide N-alkylcarbamates and their molecular docking.

  Molecules (Basel, Switzerland) 20120824

• Effect on cognition of galanthamine administered for neuromuscular block reversal in octogenarians undergoing cataract surgery.

  Anaesthesiology intensive therapy 20120808

• Production of galanthamine by Leucojum aestivum shoots grown in different bioreactor systems.

  Applied biochemistry and biotechnology 20120801

• Acetylcholinesterase inhibitors: a patent review (2008 - present).

  Expert opinion on therapeutic patents 20120801

• Gingko biloba extract EGb 761®: clinical data in dementia.

  International psychogeriatrics 20120801

• GC-MS of amaryllidaceous galanthamine-type alkaloids.

  Journal of mass spectrometry : JMS 20120801

• Effects of single treatment of anti-dementia drugs on sleep-wake patterns in rats.

  The Korean journal of physiology & pharmacology : official journal of the Korean Physiological Society and the Korean Society of Pharmacology 20120801

• Clinical practice with antidementia drugs in a geriatric clinic.

  Journal of the Medical Association of Thailand = Chotmaihet thangphaet 20120801

• Geranylphenazinediol, an acetylcholinesterase inhibitor produced by a Streptomyces species.

  Journal of natural products 20120727

• Development and evaluation of multifunctional agents for potential treatment of Alzheimer's disease: application to a pyrimidine-2,4-diamine template.

  Bioorganic & medicinal chemistry letters 20120715

• Two galantamine titration regimens in patients switched from donepezil.

  Acta neurologica Scandinavica 20120701

• The acetylcholinesterase inhibitors competitively inhibited an acetyl L-carnitine transport through the blood-brain barrier.

  Neurochemical research 20120701

• 8-[2-(2-Pentyl-cyclopropylmethyl)-cyclopropyl]-octanoic acid and its diastereomers improve age-related cognitive deterioration.

  Lipids 20120701

• Galantamine administration in chronic post-stroke aphasia.

  Journal of neurology, neurosurgery, and psychiatry 20120701

• Design, synthesis, and evaluation of indanone derivatives as acetylcholinesterase inhibitors and metal-chelating agents.

  Bioorganic & medicinal chemistry letters 20120701

• Acetylcholinesterase inhibition within the lycorine series of Amaryllidaceae alkaloids.

  Natural product communications 20120701

• Galantamine effect on tularemia pathogenesis in a BALB/c mouse model.

  Iranian biomedical journal 20120701

• Steroidal alkaloids from Holarrhena antidysenterica as acetylcholinesterase inhibitors and the investigation for structure-activity relationships.

  Life sciences 20120614

• Tacrine-silibinin codrug shows neuro- and hepatoprotective effects in vitro and pro-cognitive and hepatoprotective effects in vivo.

  Journal of medicinal chemistry 20120614

• Longitudinal changes of fractional anisotropy in Alzheimer's disease patients treated with galantamine: a 12-month randomized, placebo-controlled, double-blinded study.

  European archives of psychiatry and clinical neuroscience 20120601

• Assessing health-related quality-of-life changes in informal caregivers: an evaluation in parents of children with major congenital anomalies.

  Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation 20120601

• Galantamine-based hybrid molecules with acetylcholinesterase, butyrylcholinesterase and γ-secretase inhibition activities.

  Current Alzheimer research 20120601

• Galantamine attenuates the heroin seeking behaviors induced by cues after prolonged withdrawal in rats.

  Neuropharmacology 20120601

• From pathophysiological aspects towards unravelling the neurobiological background of cognitive deficits.

  European archives of psychiatry and clinical neuroscience 20120601

• Total synthesis of (-)-galanthamine and (-)-lycoramine via catalytic asymmetric hydrogenation and intramolecular reductive Heck cyclization.

  Organic letters 20120601

• Alzheimer's disease: early diagnosis and treatment.

  Hong Kong medical journal = Xianggang yi xue za zhi 20120601

• Adjunctive memantine therapy for cognitive impairment in chronic schizophrenia: a placebo-controlled pilot study.

  Psychiatry investigation 20120601

• ESI-MS/MS stability-indicating bioanalytical method development and validation for simultaneous estimation of donepezil, 5-desmethyl donepezil and 6-desmethyl donepezil in human plasma.

  Biomedical chromatography : BMC 20120501

• The novel object recognition memory: neurobiology, test procedure, and its modifications.

  Cognitive processing 20120501

• Mixed-effect circadian rhythm model for human erythrocyte acetylcholinesterase activity--application to the proof of concept of cholinesterase inhibition by acorn extract in healthy subjects with galantamine as positive control.

  European journal of clinical pharmacology 20120501

• Design, synthesis and evaluation of novel 16-imidazolyl substituted steroidal derivatives possessing potent diversified pharmacological properties.

  Steroids 20120501

• Simultaneous determination of antidementia drugs in human plasma: procedure transfer from HPLC-MS to UPLC-MS/MS.

  Journal of pharmaceutical and biomedical analysis 20120501

• Which cholinesterase inhibitor is the safest for the heart in elderly patients with Alzheimer's disease?

  American journal of Alzheimer's disease and other dementias 20120501

• Economic evaluation of treatment options in patients with Alzheimer's disease: a systematic review of cost-effectiveness analyses.

  Drugs 20120416

• Galantamine (Reminyl) delays cardiac ventricular repolarization and prolongs the QT interval by blocking the HERG current.

  European journal of pharmacology 20120415

• Prospective acetylcholinesterase inhibitory activity of indole and its analogs.

  Bioorganic & medicinal chemistry letters 20120415

• Combination of chronic stress and ovariectomy causes conditioned fear memory deficits and hippocampal cholinergic neuronal loss in mice.

  Neuroscience 20120405

• New pharmacological strategies for treatment of Alzheimer's disease: focus on disease modifying drugs.

  British journal of clinical pharmacology 20120401

• Acute elevations of brain kynurenic acid impair cognitive flexibility: normalization by the alpha7 positive modulator galantamine.

  Psychopharmacology 20120401

• Pharmacotherapies for Alzheimer's disease: beyond cholinesterase inhibitors.

  Pharmacology & therapeutics 20120401

• Drugs for Alzheimer's disease.

  British journal of clinical pharmacology 20120401

• Cholinesterase inhibitor adjunctive therapy for cognitive impairment and depressive symptoms in older adults with depression.

  The Annals of pharmacotherapy 20120401

• Mitochondrial dysfunction in autism spectrum disorders: a systematic review and meta-analysis.

  Molecular psychiatry 20120301

• Symptomatic and nonamyloid/tau based pharmacologic treatment for Alzheimer disease.

  Cold Spring Harbor perspectives in medicine 20120301

• Investigation of anticholinergic and non-steroidal anti-inflammatory prodrugs which reduce chemically induced skin inflammation.

  Journal of applied toxicology : JAT 20120201

• Cholinesterases inhibitory and antioxidant activities of Harpagophytum procumbens from in vitro systems.

  Phytotherapy research : PTR 20120201

• Galantamine elicits neuroprotection by inhibiting iNOS, NADPH oxidase and ROS in hippocampal slices stressed with anoxia/reoxygenation.

  Neuropharmacology 20120201

• Using functional signatures to identify repositioned drugs for breast, myelogenous leukemia and prostate cancer.

  PLoS computational biology 20120201

• Stem cells in drug screening for neurodegenerative disease.

  The Korean journal of physiology & pharmacology : official journal of the Korean Physiological Society and the Korean Society of Pharmacology 20120201

• [Pharmacological profiles of galantamine: the involvement of muscarinic receptor].

  Nihon shinkei seishin yakurigaku zasshi = Japanese journal of psychopharmacology 20120201

• Acetylcholinesterase inhibitors for schizophrenia.

  The Cochrane database of systematic reviews 20120118

• Alkaloid patterns in Leucojum aestivum shoot culture cultivated at temporary immersion conditions.

  Journal of plant physiology 20120115

• Histamine reverses a memory deficit induced in rats by early postnatal maternal deprivation.

  Neurobiology of learning and memory 20120101

• Broader considerations of higher doses of donepezil in the treatment of mild, moderate, and severe Alzheimer's disease.

  International journal of Alzheimer's disease 20120101

• Effects of cholinergic enhancing drugs on cholinergic transporters in the brain and peripheral blood lymphocytes of spontaneously hypertensive rats.

  Current Alzheimer research 20120101

• New acetylcholinesterase inhibitors for Alzheimer's disease.

  International journal of Alzheimer's disease 20120101

• A searchable cross-platform gene expression database reveals connections between drug treatments and disease.

  BMC genomics 20120101

• Systematic review on the efficacy and safety of herbal medicines for vascular dementia.

  Evidence-based complementary and alternative medicine : eCAM 20120101

• A European study investigating patterns of transition from home care towards institutional dementia care: the protocol of a RightTimePlaceCare study.

  BMC public health 20120101

• Trends in qualifying biomarkers in drug safety. Consensus of the 2011 meeting of the spanish society of clinical pharmacology.

  Frontiers in pharmacology 20120101

• Evaluating the cost effectiveness of donepezil in the treatment of Alzheimer's disease in Germany using discrete event simulation.

  BMC neurology 20120101

• Ethnobotanical treatment strategies against Alzheimer's disease.

  Current Alzheimer research 20120101

• Evaluation of the effect of Ferula asafoetida Linn. gum extract on learning and memory in Wistar rats.

  Indian journal of pharmacology 20120101

• Xirp proteins mark injured skeletal muscle in zebrafish.

  PloS one 20120101

• Using the Guttman scale to define and estimate measurement error in items over time: the case of cognitive decline and the meaning of 'points lost'.

  PloS one 20120101

• Metal chaperones: a holistic approach to the treatment of Alzheimer's disease.

  Frontiers in psychiatry 20120101

• Alpha7 nicotinic acetylcholine receptor is a target in pharmacology and toxicology.

  International journal of molecular sciences 20120101

• Small molecule screening platform for assessment of cardiovascular toxicity on adult zebrafish heart.

  BMC physiology 20120101

• Antioxidant enzymatic activities in Alzheimer's disease: the relationship to acetylcholinesterase inhibitors.

  Journal of Alzheimer's disease : JAD 20120101

• Effect of toki-shakuyaku-san on regional cerebral blood flow in patients with mild cognitive impairment and Alzheimer's disease.

  Evidence-based complementary and alternative medicine : eCAM 20120101

• A qualitative evaluation of general practitioners' perceptions regarding access to medicines in New Zealand.

  BMJ open 20120101

• β-Secretases, Alzheimer's Disease, and Down Syndrome.

  Current gerontology and geriatrics research 20120101

• Genomics of Dementia: APOE- and CYP2D6-Related Pharmacogenetics.

  International journal of Alzheimer's disease 20120101

• Development of on-line high performance liquid chromatography (HPLC)-biochemical detection methods as tools in the identification of bioactives.

  International journal of molecular sciences 20120101

• Centella asiatica Extract Improves Behavioral Deficits in a Mouse Model of Alzheimer's Disease: Investigation of a Possible Mechanism of Action.

  International journal of Alzheimer's disease 20120101

• The economic impact of galantamine vs placebo: an analysis based on functional capacity in a Swedish cohort study.

  Journal of medical economics 20120101

• RACK1 is a ribosome scaffold protein for β-actin mRNA/ZBP1 complex.

  PloS one 20120101

• Alzheimer's disease: a clinical practice-oriented review.

  Frontiers in neurology 20120101

• Secondary Metabolites from Plants Inhibiting ABC Transporters and Reversing Resistance of Cancer Cells and Microbes to Cytotoxic and Antimicrobial Agents.

  Frontiers in microbiology 20120101

• Novel therapeutics in Alzheimer's disease.

  International journal of Alzheimer's disease 20120101

• Neuroprotective effects of meloxicam and selegiline in scopolamine-induced cognitive impairment and oxidative stress.

  International journal of Alzheimer's disease 20120101

• The effectiveness and cost-effectiveness of donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (review of Technology Appraisal No. 111): a systematic review and economic model.

  Health technology assessment (Winchester, England) 20120101

• Age-related neurodegeneration and memory loss in down syndrome.

  Current gerontology and geriatrics research 20120101

• [New anti-AD drugs--their possibilities and issues].

  Seishin shinkeigaku zasshi = Psychiatria et neurologia Japonica 20120101

• [Strategy and perspectives for development of Alzheimer disease-modifying drugs].

  Seishin shinkeigaku zasshi = Psychiatria et neurologia Japonica 20120101

• Behavioral and psychological symptoms of dementia.

  Frontiers in neurology 20120101

• Donepezil combined with natural hirudin improves the clinical symptoms of patients with mild-to-moderate Alzheimer's disease: a 20-week open-label pilot study.

  International journal of medical sciences 20120101

• A novel subject synchronization clinical trial design for Alzheimer's disease.

  Journal of Alzheimer's disease : JAD 20120101

• The therapeutic effect of memantine through the stimulation of synapse formation and dendritic spine maturation in autism and fragile X syndrome.

  PloS one 20120101

• Use of cognitive enhancers for mild cognitive impairment: protocol for a systematic review and network meta-analysis.

  Systematic reviews 20120101

• Treatment-resistant Schizophrenia: Evidence-based Strategies.

  Mens sana monographs 20120101

• Increased Orbitofrontal Brain Activation after Administration of a Selective Adenosine A(2A) Antagonist in Cocaine Dependent Subjects.

  Frontiers in psychiatry 20120101

• Cognitive dysfunction in multiple sclerosis.

  Frontiers in neurology 20120101

• A combination of galantamine and memantine modifies cognitive function in subjects with amnestic MCI.

  The journal of nutrition, health & aging 20120101

• Neuroprotective Activity of Sibjeondaebo-tang on Aβ Peptide-Induced Damages.

  Evidence-based complementary and alternative medicine : eCAM 20120101

• Intranasal 'painless' human Nerve Growth Factor [corrected] slows amyloid neurodegeneration and prevents memory deficits in App X PS1 mice.

  PloS one 20120101

• Wading pools, fading memories-place navigation in transgenic mouse models of Alzheimer's disease.

  Frontiers in aging neuroscience 20120101

• Bipolar disorder: clinical perspectives and implications with cognitive dysfunction and dementia.

  Depression research and treatment 20120101

• Controlled release reservoir mini tablets approach for controlling the drug release of Galantamine Hydrobromide.

  Pharmaceutical development and technology 20120101

• Dietary polyphenols as modulators of brain functions: biological actions and molecular mechanisms underpinning their beneficial effects.

  Oxidative medicine and cellular longevity 20120101

• Efficacy of cognitive enhancers for Alzheimer's disease: protocol for a systematic review and network meta-analysis.

  Systematic reviews 20120101

• Transdermal donepezil on the treatment of Alzheimer's disease.

  Neuropsychiatric disease and treatment 20120101

• Synthesis, biological evaluation, and molecular modeling of donepezil and N-[(5-(benzyloxy)-1-methyl-1H-indol-2-yl)methyl]-N-methylprop-2-yn-1-amine hybrids as new multipotent cholinesterase/monoamine oxidase inhibitors for the treatment of Alzheimer's disease.

  Journal of medicinal chemistry 20111222

• Polymorphic microsatellite loci for the genetic analysis of Lycoris radiata (Amaryllidaceae) and cross-amplification in other congeneric species.

  Genetics and molecular research : GMR 20111219

• Role of cholinergic markers on memory function of rats exposed to hypobaric hypoxia.

  European journal of pharmacology 20111215

• Donepezil, but not galantamine, blocks muscarinic receptor-mediated in vitro and in vivo responses.

  Synapse (New York, N.Y.) 20111201

• Galantamine counteracts development of learning impairment in guinea pigs exposed to the organophosphorus poison soman: clinical significance.

  Neurotoxicology 20111201

• Competitive binding at a nicotinic receptor transmembrane site of two α7-selective positive allosteric modulators with differing effects on agonist-evoked desensitization.

  Neuropharmacology 20111201

• Acetylcholinesterase inhibitors rapidly activate Trk neurotrophin receptors in the mouse hippocampus.

  Neuropharmacology 20111201

• Synergistic inhibition of butyrylcholinesterase by galantamine and citalopram.

  Biochimica et biophysica acta 20111201

• The coumarin scopoletin potentiates acetylcholine release from synaptosomes, amplifies hippocampal long-term potentiation and ameliorates anticholinergic- and age-impaired memory.

  Neuroscience 20111201

• Benzenediol-berberine hybrids: multifunctional agents for Alzheimer's disease.

  Bioorganic & medicinal chemistry 20111201

• Medicinal plants and dementia therapy: herbal hopes for brain aging?

  CNS neuroscience & therapeutics 20111201

• Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).

  PLoS computational biology 20111201

• Sundown syndrome in persons with dementia: an update.

  Psychiatry investigation 20111201

• Isolation and cholinesterase activity of Amaryllidaceae alkaloids from Nerine bowdenii.

  Natural product communications 20111201

• Alzheimer's dementia: current data review.

  Collegium antropologicum 20111201

• The neurotrophins and their role in Alzheimer's disease.

  Current neuropharmacology 20111201

• [Galantamine].

  Nihon rinsho. Japanese journal of clinical medicine 20111201

• Kinetic study of the rearrangement of deuterium-labeled 4'-O-methylnorbelladine in Leucojum aestivum shoot cultures by mass spectrometry. Influence of precursor feeding on amaryllidaceae alkaloid accumulation.

  Journal of natural products 20111128

• Acetylcholinesterase-inhibiting alkaloids from Zephyranthes concolor.

  Molecules (Basel, Switzerland) 20111115

• Galantamine and behavior in Alzheimer disease: analysis of four trials.

  Acta neurologica Scandinavica 20111101

• BCHE and CYP2D6 genetic variation in Alzheimer's disease patients treated with cholinesterase inhibitors.

  European journal of clinical pharmacology 20111101

• Effects of galantamine in Alzheimer's disease: double-blind withdrawal studies evaluating sustained versus interrupted treatment.

  Current Alzheimer research 20111101

• Symmetrical corticobasal syndrome caused by a novel C.314dup progranulin mutation.

  Journal of molecular neuroscience : MN 20111101

• Galanthamine plus estradiol treatment enhances cognitive performance in aged ovariectomized rats.

  Hormones and behavior 20111101

• Effective pharmacological management of Alzheimer's disease.

  The American journal of managed care 20111101

• The costs of Alzheimer's disease and the value of effective therapies.

  The American journal of managed care 20111101

• Galantamine rescues lead-impaired synaptic plasticity in rat dentate gyrus.

  Toxicology 20111028

• Current and emerging drug treatment options for Alzheimer's disease: a systematic review.

  Drugs 20111022

• Structural features and hydrogen-bond properties of galanthamine and codeine: an experimental and theoretical study.

  Chemistry (Weinheim an der Bergstrasse, Germany) 20111004

• Effects of a new synthetic butyrylcholinesterase inhibitor, HBU-39, on cell proliferation and neuroblast differentiation in the hippocampal dentate gyrus in a scopolamine-induced amnesia animal model.

  Neurochemistry international 20111001

• Effects of cholinesterase inhibitors in Parkinson's disease dementia: a review of clinical data.

  CNS neuroscience & therapeutics 20111001

• Pharmacological treatment of Alzheimer disease.

  Canadian journal of psychiatry. Revue canadienne de psychiatrie 20111001

• The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the non-motor symptoms of Parkinson's disease.

  Movement disorders : official journal of the Movement Disorder Society 20111001

• Biological active compounds from Georgian Galanthus shaoricus.

  Georgian medical news 20111001

• The effects of galantamine on nicotine withdrawal-induced deficits in contextual fear conditioning in C57BL/6 mice.

  Behavioural brain research 20110930

• Non-enzymatic pretreatment of nerve agent (soman) poisoning: a brief state-of-the-art review.

  Toxicology letters 20110925

• 1,3-substituted imidazolidine-2,4,5-triones: synthesis and inhibition of cholinergic enzymes.

  Molecules (Basel, Switzerland) 20110905

• Cholinergic hypofunction impairs memory acquisition possibly through hippocampal Arc and BDNF downregulation.

  Hippocampus 20110901

• Oral tremor induced by galantamine in rats: a model of the parkinsonian side effects of cholinomimetics used to treat Alzheimer's disease.

  Pharmacology, biochemistry, and behavior 20110901

• Negative argument for debate with V. O. Emery for J Neural Transmission : Alzheimer's disease: are we intervening too late? No we are not. Con.

  Journal of neural transmission (Vienna, Austria : 1996) 20110901

• An overview on natural cholinesterase inhibitors--a multi-targeted drug class--and their mass production.

  Mini reviews in medicinal chemistry 20110901

• Primary progressive aphasias and their contribution to the contemporary knowledge about the brain-language relationship.

  Neuropsychology review 20110901

• Pharmacologists and Alzheimer disease therapy: to boldly go where no scientist has gone before.

  Expert opinion on investigational drugs 20110901

• Effects of cholinesterase inhibitors on postoperative outcomes of older adults with dementia undergoing hip fracture surgery.

  The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry 20110901

• [Pharmacological and clinical profiles of galantamine (Reminyl(®))].

  Nihon yakurigaku zasshi. Folia pharmacologica Japonica 20110901

• Efficacy and safety of switching from oral cholinesterase inhibitors to the rivastigmine transdermal patch in patients with probable Alzheimer's disease.

  Journal of clinical neurology (Seoul, Korea) 20110901

• Asymmetric synthesis of bioactive hydrodibenzofuran alkaloids: (-)-lycoramine, (-)-galanthamine, and (+)-lunarine.

  Angewandte Chemie (International ed. in English) 20110822

• Alkaloids from Hippeastrum papilio.

  Molecules (Basel, Switzerland) 20110818

• Clinical practice with anti-dementia drugs: a revised (second) consensus statement from the British Association for Psychopharmacology.

  Journal of psychopharmacology (Oxford, England) 20110801

• A new test of the construct validity of the CarerQol instrument: measuring the impact of informal care giving.

  Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation 20110801

• Synthesis and biological activity of derivatives of tetrahydroacridine as acetylcholinesterase inhibitors.

  Bioorganic chemistry 20110801

• Cytochrome P450 2D6 phenotyping in an elderly population with dementia and response to galantamine in dementia: a pilot study.

  The American journal of geriatric pharmacotherapy 20110801

• [Newly approved drugs for Alzheimer disease: effectiveness and limitation].

  Brain and nerve = Shinkei kenkyu no shinpo 20110801

• New drugs for Alzheimer's disease in Japan.

  Psychiatry and clinical neurosciences 20110801

• Acetylcholinesterase inhibition by somes promising Brazilian medicinal plants.

  Brazilian journal of biology = Revista brasleira de biologia 20110801

• Vascular dementia.

  Chonnam medical journal 20110801

• Galantamine (Reminyl) once daily outcome and satisfaction survey (RODOS) in mild to moderate Alzheimer's disease: a study in a real life population.

  Geriatrics & gerontology international 20110701

• [Daily functioning in dementia: pharmacological and non-pharmacological interventions demonstrate small effects on heterogeneous scales].

  Psychiatrische Praxis 20110701

• [Prescription differences of dementia drugs in urban and rural areas in Germany].

  Psychiatrische Praxis 20110701

• Mycobacterium tuberculosis and cholinesterase inhibitors from Voacanga globosa.

  European journal of medicinal chemistry 20110701

• Combination therapy for Alzheimer's disease.

  Drugs & aging 20110701

• Effects of adjunct galantamine to risperidone, or haloperidol, in animal models of antipsychotic activity and extrapyramidal side-effect liability: involvement of the cholinergic muscarinic receptor.

  The international journal of neuropsychopharmacology 20110601

• VAChT knock-down mice show normal prepulse inhibition but disrupted long-term habituation.

  Genes, brain, and behavior 20110601

• In vitro antioxidant, anticholinesterase and antimicrobial activity studies on three Agaricus species with fatty acid compositions and iron contents: a comparative study on the three most edible mushrooms.

  Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association 20110601

• N-acylaminophenothiazines: neuroprotective agents displaying multifunctional activities for a potential treatment of Alzheimer's disease.

  European journal of medicinal chemistry 20110601

• Quinolizidinyl derivatives of bi- and tricyclic systems as potent inhibitors of acetyl- and butyrylcholinesterase with potential in Alzheimer's disease.

  European journal of medicinal chemistry 20110601

• The role of phytochemicals in the treatment and prevention of dementia.

  Drugs & aging 20110601

• Design, synthesis and biological evaluation of new 2-benzoxazolinone derivatives as potential cholinesterase inhibitors for therapy of alzheimer's disease.

  Die Pharmazie 20110601

• In silico design and search for acetylcholinesterase inhibitors in Alzheimer's disease with a suitable pharmacokinetic profile and low toxicity.

  Future medicinal chemistry 20110601

• Galantamine potentiates the protective effect of rofecoxib and caffeic acid against intrahippocampal Kainic acid-induced cognitive dysfunction in rat.

  Brain research bulletin 20110530

• Possible role of cholinesterase inhibitors on memory consolidation following hypobaric hypoxia of rats.

  The International journal of neuroscience 20110501

• Drug delivery strategies for Alzheimer's disease treatment.

  Expert opinion on drug delivery 20110501

• Effects of galantamine on cocaine use in chronic cocaine users.

  The American journal on addictions 20110501

• Alternative drug therapies for dementia.

  Journal of psychosocial nursing and mental health services 20110501

• Analgesic and antineuropathic drugs acting through central cholinergic mechanisms.

  Recent patents on CNS drug discovery 20110501

• In Salvia miltiorrhiza, phenolic acids possess protective properties against amyloid β-induced cytotoxicity, and tanshinones act as acetylcholinesterase inhibitors.

  Environmental toxicology and pharmacology 20110501

• Stability-indicating study of the anti-Alzheimer's drug galantamine hydrobromide.

  Journal of pharmaceutical and biomedical analysis 20110428

• Effect of fertilizers on galanthamine and metabolite profiles in Narcissus bulbs by 1H NMR.

  Journal of agricultural and food chemistry 20110413

• Antioxidant and anticholinesterase constituents from the petroleum ether and chloroform extracts of Iris suaveolens.

  Phytotherapy research : PTR 20110401

• Switching cholinesterase inhibitors in older adults with dementia.

  International psychogeriatrics 20110401

• Metabolic profiling of 3-nitropropionic acid early-stage Huntington's disease rat model using gas chromatography time-of-flight mass spectrometry.

  Journal of proteome research 20110401

• Synthesis of (-)-homogalanthamine from naltrexone.

  The Journal of organic chemistry 20110401

• Simultaneous determination of antidementia drugs in human plasma for therapeutic drug monitoring.

  Therapeutic drug monitoring 20110401

• Synthesis, biological evaluation and molecular modeling of novel triazole-containing berberine derivatives as acetylcholinesterase and β-amyloid aggregation inhibitors.

  Bioorganic & medicinal chemistry 20110401

• Design, synthesis and structure-activity relationship (SAR) studies of 2,4-disubstituted pyrimidine derivatives: dual activity as cholinesterase and Aβ-aggregation inhibitors.

  Bioorganic & medicinal chemistry 20110401

• Newer molecules in the treatment of schizophrenia: A clinical update.

  Indian journal of pharmacology 20110401

• Pharmaco-genetically guided treatment of recurrent rage outbursts in an adult male with 15q13.3 deletion syndrome.

  American journal of medical genetics. Part A 20110401

• Bradycardia due to cholinesterase inhibitors: identify adverse effects and take them into account.

  Prescrire international 20110401

• Physical activity attenuates neuropsychiatric disturbances and caregiver burden in patients with dementia.

  Clinics (Sao Paulo, Brazil) 20110401

• Prescribing trends in cognition enhancing drugs in Australia.

  International psychogeriatrics 20110301

• Treatment efficacy in a soman-poisoned guinea pig model: added value of physostigmine?

  Archives of toxicology 20110301

• Molecular cloning and characterization of a phenylalanine ammonia-lyase gene (LrPAL) from Lycoris radiata.

  Molecular biology reports 20110301

• Advances in mass spectrometry-based post-column bioaffinity profiling of mixtures.

  Analytical and bioanalytical chemistry 20110301

• Synapse- and subtype-specific modulation of synaptic transmission by nicotinic acetylcholine receptors in the ventrobasal thalamus.

  Neuroscience research 20110301

• Pharmacokinetic and pharmacodynamic properties of cholinesterase inhibitors donepezil, tacrine, and galantamine in aged and young Lister hooded rats.

  Drug metabolism and disposition: the biological fate of chemicals 20110301

• Long-term response to galantamine in relation to short-term efficacy data: pooled analysis in patients with mild to moderate Alzheimer's disease.

  Current Alzheimer research 20110301

• Beneficial effect of repetitive transcranial magnetic stimulation combined with cognitive training for the treatment of Alzheimer's disease: a proof of concept study.

  Journal of neural transmission (Vienna, Austria : 1996) 20110301

• Cardio-vascular safety of acetyl cholinesterase inhibitors in patients suffering from Alzheimer's disease; factors that predict poor tolerability.

  International journal of geriatric psychiatry 20110301

• Managing cognitive dysfunction through the continuum of Alzheimer's disease: role of pharmacotherapy.

  CNS drugs 20110301

• Effectiveness of adding memantine to an Alzheimer dementia treatment regimen which already includes stable donepezil therapy: a critically appraised topic.

  The neurologist 20110301

• Antioxidant activity of a Mediterranean food product: 'fig syrup'.

  Nutrients 20110301

• Development and validation of a GC-MS method for rapid determination of galanthamine in Leucojum aestivum and Narcissus ssp.: a metabolomic approach.

  Talanta 20110215

• Risk factors for nursing home placement in Alzheimer's disease: a longitudinal study of cognition, ADL, service utilization, and cholinesterase inhibitor treatment.

  The Gerontologist 20110201

• Galantamine augmentation of long-acting injectable risperidone for cognitive impairments in chronic schizophrenia.

  Schizophrenia research 20110201

• Binding of huperzine A and galanthamine to acetylcholinesterase, based on ONIOM method.

  Nanomedicine : nanotechnology, biology, and medicine 20110201

• Involvement of decreased muscarinic receptor function in prepulse inhibition deficits in mice reared in social isolation.

  British journal of pharmacology 20110201

• Acetylcholinesterase inhibitors partially generalize to nicotine discriminative stimulus effect in rats.

  Behavioural pharmacology 20110201

• Probing the mid-gorge of cholinesterases with spacer-modified bivalent quinazolinimines leads to highly potent and selective butyrylcholinesterase inhibitors.

  Bioorganic & medicinal chemistry 20110201

• Safety and tolerability of galantamine SA in dementia patients transitioned from donepezil.

  The Consultant pharmacist : the journal of the American Society of Consultant Pharmacists 20110201

• Psychotropic medication use among elderly nursing home residents in Slovenia: cross-sectional study.

  Croatian medical journal 20110201

• Galantamine improves sustained attention in chronic cocaine users.

  Experimental and clinical psychopharmacology 20110201

• Biotransformation of turmerones by Aspergillus niger.

  Journal of natural products 20110128

• Ion mobility spectrometry: a valuable tool for kinetic studies in enzymology.

  Analytica chimica acta 20110124

• A systematic review of single chinese herbs for Alzheimer's disease treatment.

  Evidence-based complementary and alternative medicine : eCAM 20110101

• Protective Effects of Rosa damascena and Its Active Constituent on Aβ(25-35)-Induced Neuritic Atrophy.

  Evidence-based complementary and alternative medicine : eCAM 20110101

• Galanthamine and related alkaloids production by Leucojum aestivum L. shoot culture using a temporary immersion technology.

  Applied biochemistry and biotechnology 20110101

• Long-term outcome and prediction models of activities of daily living in Alzheimer disease with cholinesterase inhibitor treatment.

  Alzheimer disease and associated disorders 20110101

• Respiratory myoclonus, a side effect of galantamine.

  Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria 20110101

• Silanetriols as in vitro inhibitors for AChE.

  Bioorganic & medicinal chemistry letters 20110101

• Cognitive enhancement by drugs in health and disease.

  Trends in cognitive sciences 20110101

• Long-term effects of galantamine treatment on brain functional activities as measured by PET in Alzheimer's disease patients.

  Journal of Alzheimer's disease : JAD 20110101

• The discovery of potential acetylcholinesterase inhibitors: a combination of pharmacophore modeling, virtual screening, and molecular docking studies.

  Journal of biomedical science 20110101

• Protective effect of curcumin (Curcuma longa) against D-galactose-induced senescence in mice.

  Journal of Asian natural products research 20110101

• Alkaloid diversity in Galanthus elwesii and Galanthus nivalis.

  Chemistry & biodiversity 20110101

• Progressive cholinergic decline in Alzheimer's Disease: consideration for treatment with donepezil 23 mg in patients with moderate to severe symptomatology.

  BMC neurology 20110101

• Stimulating nicotinic receptors trigger multiple pathways attenuating cytotoxicity in models of Alzheimer's and Parkinson's diseases.

  Journal of Alzheimer's disease : JAD 20110101

• Cognitive-enhancing effects of polygalasaponin hydrolysate in aβ(25-35)-induced amnesic mice.

  Evidence-based complementary and alternative medicine : eCAM 20110101

• Rehabilitating a brain with Alzheimer's: a proposal.

  Clinical interventions in aging 20110101

• Association between prescription of conventional or atypical antipsychotic drugs and mortality in older persons with Alzheimer's disease.

  Dementia and geriatric cognitive disorders 20110101

• Pharmacological aspects of the acetylcholinesterase inhibitor galantamine.

  Journal of pharmacological sciences 20110101

• Masitinib as an adjunct therapy for mild-to-moderate Alzheimer's disease: a randomised, placebo-controlled phase 2 trial.

  Alzheimer's research & therapy 20110101

• [Cholinesterase blockers in anesthesiology: a replenishment of former arsenal].

  Anesteziologiia i reanimatologiia 20110101

• Drug discovery from Chinese medicine against neurodegeneration in Alzheimer's and vascular dementia.

  Chinese medicine 20110101

• Alleviating neuropsychiatric symptoms in dementia: the effects of Ginkgo biloba extract EGb 761. Findings from a randomized controlled trial.

  Neuropsychiatric disease and treatment 20110101

• Cessation versus continuation of galantamine treatment after 12 months of therapy in patients with Alzheimer's disease: a randomized, double blind, placebo controlled withdrawal trial.

  Journal of Alzheimer's disease : JAD 20110101

• Bacopa monniera Attenuates Scopolamine-Induced Impairment of Spatial Memory in Mice.

  Evidence-based complementary and alternative medicine : eCAM 20110101

• Chronic fatigue syndrome.

  BMJ clinical evidence 20110101

• Age sensitivity of behavioral tests and brain substrates of normal aging in mice.

  Frontiers in aging neuroscience 20110101

• Clinical features and multidisciplinary approaches to dementia care.

  Journal of multidisciplinary healthcare 20110101

• Neuroprotective effects of marine algae.

  Marine drugs 20110101

• Analyzing the impact of 23 mg/day donepezil on language dysfunction in moderate to severe Alzheimer's disease.

  Alzheimer's research & therapy 20110101

• Mitochondrial therapeutics in Alzheimer's disease and Parkinson's disease.

  Alzheimer's research & therapy 20110101

• The 'aged garlic extract:' (AGE) and one of its active ingredients S-allyl-L-cysteine (SAC) as potential preventive and therapeutic agents for Alzheimer's disease (AD).

  Current medicinal chemistry 20110101

• Galantamine alleviates inflammation and other obesity-associated complications in high-fat diet-fed mice.

  Molecular medicine (Cambridge, Mass.) 20110101

• Donepezil, anti-Alzheimer's disease drug, prevents cardiac rupture during acute phase of myocardial infarction in mice.

  PloS one 20110101

• Transcranial magnetic stimulation studies in Alzheimer's disease.

  International journal of Alzheimer's disease 20110101

• Pharmacological and physiological characterization of the tremulous jaw movement model of parkinsonian tremor: potential insights into the pathophysiology of tremor.

  Frontiers in systems neuroscience 20110101

• Predictors of long-term cognitive outcome in Alzheimer's disease.

  Alzheimer's research & therapy 20110101

• Open-label study of the short-term effects of memantine on FDG-PET in frontotemporal dementia.

  Neuropsychiatric disease and treatment 20110101

• Rivastigmine lowers Aβ and increases sAPPα levels, which parallel elevated synaptic markers and metabolic activity in degenerating primary rat neurons.

  PloS one 20110101

• Cost-effectiveness analysis of memantine for moderate-to-severe Alzheimer's disease in the Netherlands.

  Neuropsychiatric disease and treatment 20110101

• Prescribing patterns in dementia: a multicentre observational study in a German network of CAM physicians.

  BMC neurology 20110101

• Age-related white matter changes.

  Journal of aging research 20110101

• Long-term effects of galantamine on cognitive function in Alzheimer's disease: a large-scale international retrospective study.

  Journal of Alzheimer's disease : JAD 20110101

• Donepezil impairs memory in healthy older subjects: behavioural, EEG and simultaneous EEG/fMRI biomarkers.

  PloS one 20110101

• Examining brain-cognition effects of ginkgo biloba extract: brain activation in the left temporal and left prefrontal cortex in an object working memory task.

  Evidence-based complementary and alternative medicine : eCAM 20110101

• Interactions of AChE with Aβ Aggregates in Alzheimer's Brain: Therapeutic Relevance of IDN 5706.

  Frontiers in molecular neuroscience 20110101

• Revisiting the Role of Acetylcholinesterase in Alzheimer's Disease: Cross-Talk with P-tau and β-Amyloid.

  Frontiers in molecular neuroscience 20110101

• Quality of online pharmacies and websites selling prescription drugs: a systematic review.

  Journal of medical Internet research 20110101

• Meningitic Escherichia coli K1 penetration and neutrophil transmigration across the blood-brain barrier are modulated by alpha7 nicotinic receptor.

  PloS one 20110101

• Market Access Agreements for pharmaceuticals in Europe: diversity of approaches and underlying concepts.

  BMC health services research 20110101

• Progress in understanding variability in cognitive responses to cholinesterase inhibitor treatment.

  Alzheimer's research & therapy 20110101

• Galantamine treatment in Alzheimer's disease: response and long-term outcome in a routine clinical setting.

  Neuropsychiatric disease and treatment 20110101

• Drug utilization study of psychotropic drugs in outdoor patients in a teaching hospital.

  Indian journal of psychological medicine 20110101

• [Sleep disorders in patients with dementia in Parkinson's disease].

  Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova 20110101

• Biomarkers to measure treatment effects in Alzheimer's disease: what should we look for?

  International journal of Alzheimer's disease 20110101

• Impact of early intervention and disease modification in patients with predementia Alzheimer's disease: a Markov model simulation.

  ClinicoEconomics and outcomes research : CEOR 20110101

• Differential immediate and sustained memory enhancing effects of alpha7 nicotinic receptor agonists and allosteric modulators in rats.

  PloS one 20110101

• State-of-the-Art Automated Patch Clamp Devices: Heat Activation, Action Potentials, and High Throughput in Ion Channel Screening.

  Frontiers in pharmacology 20110101

• Molecular imaging in Alzheimer's disease: new perspectives on biomarkers for early diagnosis and drug development.

  Alzheimer's research & therapy 20110101

• Targeting acetylcholinesterase: identification of chemical leads by high throughput screening, structure determination and molecular modeling.

  PloS one 20110101

• Impact of geriatric comorbidity and polypharmacy on cholinesterase inhibitors prescribing in dementia.

  BMC psychiatry 20110101

• Patient self-report for evaluating mild cognitive impairment and prodromal Alzheimer's disease.

  Alzheimer's research & therapy 20110101

• Amnestic mild cognitive impairment and early Alzheimer's disease in an asian memory clinic - evidence for a clinical spectrum.

  Dementia and geriatric cognitive disorders extra 20110101

• A 24-week, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety and tolerability of the rivastigmine patch in Japanese patients with Alzheimer's disease.

  Dementia and geriatric cognitive disorders extra 20110101

• The efficacy of licensed-indication use of donepezil and memantine monotherapies for treating behavioural and psychological symptoms of dementia in patients with Alzheimer's disease: systematic review and meta-analysis.

  Dementia and geriatric cognitive disorders extra 20110101

• [The application of multichannel electrostimulation and nivalin electrophoresis for the rehabilitative treatment of the patient following plastic surgery in the facial region].

  Voprosy kurortologii, fizioterapii, i lechebnoi fizicheskoi kultury 20110101

• Huperzine induces alteration in oxidative balance and antioxidants in a guinea pig model.

  Neuro endocrinology letters 20110101

• A novel neurotrophic drug for cognitive enhancement and Alzheimer's disease.

  PloS one 20110101

• Liposomes for Targeted Delivery of Active Agents against Neurodegenerative Diseases (Alzheimer's Disease and Parkinson's Disease).

  Journal of drug delivery 20110101

• Transcriptional response of zebrafish embryos exposed to neurotoxic compounds reveals a muscle activity dependent hspb11 expression.

  PloS one 20110101

• ENU mutagenesis screen to establish motor phenotypes in wild-type mice and modifiers of a pre-existing motor phenotype in tau mutant mice.

  Journal of biomedicine & biotechnology 20110101

• Matrix metalloproteinases contribute to neuronal dysfunction in animal models of drug dependence, Alzheimer's disease, and epilepsy.

  Biochemistry research international 20110101

• Galantamine improves olfactory learning in the Ts65Dn mouse model of Down syndrome.

  Scientific reports 20110101

• [The application of electrical stimulation by bipolar pulsed currents and galanthamine electrophoresis for the rehabilitation of patients with diabetes mellitus].

  Voprosy kurortologii, fizioterapii, i lechebnoi fizicheskoi kultury 20110101

• Galantamine-induced amyloid-{beta} clearance mediated via stimulation of microglial nicotinic acetylcholine receptors.

  The Journal of biological chemistry 20101217

• Alkaloids from stems of Esenbeckia leiocarpa Engl. (Rutaceae) as potential treatment for Alzheimer disease.

  Molecules (Basel, Switzerland) 20101213

• Structural insights to investigate Conypododiol as a dual cholinesterase inhibitor from Asparagus adscendens.

  Fitoterapia 20101201

• Identification of non-alkaloid acetylcholinesterase inhibitors from Ferulago campestris (Besser) Grecescu (Apiaceae).

  Fitoterapia 20101201

• Localization by site-directed mutagenesis of a galantamine binding site on α7 nicotinic acetylcholine receptor extracellular domain.

  Journal of receptor and signal transduction research 20101201

• Frontotemporal dementia: a review for primary care physicians.

  American family physician 20101201

• Alzheimer's disease: aging, insomnia and epigenetics.

  Taiwanese journal of obstetrics & gynecology 20101201

• Vascular cognitive impairment: Current concepts and Indian perspective.

  Annals of Indian Academy of Neurology 20101201

• Triterpenoidal alkaloids from Buxus natalensis and their acetylcholinesterase inhibitory activity.

  Journal of natural products 20101129

• Citrusosides A-D and furanocoumarins with cholinesterase inhibitory activity from the fruit peels of Citrus hystrix.

  Journal of natural products 20101129

• Galantamine ameliorates the impairment of recognition memory in mice repeatedly treated with methamphetamine: involvement of allosteric potentiation of nicotinic acetylcholine receptors and dopaminergic-ERK1/2 systems.

  The international journal of neuropsychopharmacology 20101101

• Effects of galantamine on β-amyloid release and beta-site cleaving enzyme 1 expression in differentiated human neuroblastoma SH-SY5Y cells.

  Experimental gerontology 20101101

• Protective effects of galantamine against Abeta-induced PC12 cell apoptosis by preventing mitochondrial dysfunction and endoplasmic reticulum stress.

  Neurochemistry international 20101101

• Indole alkaloids from Ervatamia hainanensis with potent acetylcholinesterase inhibition activities.

  Bioorganic & medicinal chemistry letters 20101101

• The pharmacoeconomics of cognitive enhancers in moderate to severe Alzheimer's disease.

  CNS drugs 20101101

• Pattern electroretinogram (PERG) and pattern visual evoked potential (PVEP) in the early stages of Alzheimer's disease.

  Documenta ophthalmologica. Advances in ophthalmology 20101001

• Regulation of peripheral inflammation by the central nervous system.

  Current rheumatology reports 20101001

• [Beneficial effect of galantamine on sensory information-processing deficits].

  Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan 20101001

• Effects of cholinergic agonists and antagonists under conditions of spleen denervation in rats with endotoxic shock.

  Bulletin of experimental biology and medicine 20101001

• Evaluation of the effects of galantamine on cardiac function in elderly patients with Alzheimer's disease.

  The American journal of geriatric pharmacotherapy 20101001

• Adult neurogenesis and neural stem cells as a model for the discovery and development of novel drugs.

  Expert opinion on drug discovery 20101001

• Cortical kynurenic acid bi-directionally modulates prefrontal glutamate levels as assessed by microdialysis and rapid electrochemistry.

  Neuroscience 20100915

• Galangin, a flavonol derived from Rhizoma Alpiniae Officinarum, inhibits acetylcholinesterase activity in vitro.

  Chemico-biological interactions 20100906

• Drug treatment of Alzheimer's disease patients leads to expression changes in peripheral blood cells.

  Alzheimer's & dementia : the journal of the Alzheimer's Association 20100901

• Synergistic neuroprotective effect of combined low concentrations of galantamine and melatonin against oxidative stress in SH-SY5Y neuroblastoma cells.

  Journal of pineal research 20100901

• Pretreatment of Guinea pigs with galantamine prevents immediate and delayed effects of soman on inhibitory synaptic transmission in the hippocampus.

  The Journal of pharmacology and experimental therapeutics 20100901

• Structure-activity studies on acetylcholinesterase inhibition in the lycorine series of Amaryllidaceae alkaloids.

  Bioorganic & medicinal chemistry letters 20100901

• Current treatments for patients with Alzheimer disease.

  The Journal of the American Osteopathic Association 20100901

• [Treatment of Alzheimer's disease: the current situation?].

  Revue medicale de Bruxelles 20100901

• Galantamine inhibits calpain-calcineurin signaling activated by beta-amyloid in human neuroblastoma SH-SY5Y cells.

  Neuroscience letters 20100823

• Multipotent drugs with cholinergic and neuroprotective properties for the treatment of Alzheimer and neuronal vascular diseases. I. Synthesis, biological assessment, and molecular modeling of simple and readily available 2-aminopyridine-, and 2-chloropyridine-3,5-dicarbonitriles.

  Bioorganic & medicinal chemistry 20100815

• Predictors of adherence among Alzheimer's disease patients receiving oral therapy.

  Current medical research and opinion 20100801

• Discontinuation of cholinesterase inhibitor treatment and determinants thereof in the Netherlands: A retrospective cohort study.

  Drugs & aging 20100801

• Determination of galanthamine in Bulbus Lycoridis Radiatae by coupling capillary electrophoresis with end-column electrochemiluminescence detection.

  Journal of separation science 20100801

• Synthesis, inhibitory activity of cholinesterases, and neuroprotective profile of novel 1,8-naphthyridine derivatives.

  Journal of medicinal chemistry 20100722

• Morphinans and isoquinolines: acetylcholinesterase inhibition, pharmacophore modeling, and interaction with opioid receptors.

  Bioorganic & medicinal chemistry 20100715

• Effect of isoquinoline alkaloids from two Hippeastrum species on in vitro acetylcholinesterase activity.

  Phytomedicine : international journal of phytotherapy and phytopharmacology 20100701

• [S3 guidelines on dementia. Symptomatic therapy of dementia].

  Der Nervenarzt 20100701

• [Development of new drugs for Alzheimer's disease].

  Brain and nerve = Shinkei kenkyu no shinpo 20100701

• Effect of cholinesterase inhibitor galanthamine on circulating tumor necrosis factor alpha in rats with lipopolysaccharide-induced peritonitis.

  Chinese medical journal 20100701

• Spectrofluorimetry in organized media coupled to second-order multivariate calibration for the determination of galantamine in the presence of uncalibrated interferences.

  Talanta 20100630

• Synthesis and biological evaluation of a new series of berberine derivatives as dual inhibitors of acetylcholinesterase and butyrylcholinesterase.

  Bioorganic & medicinal chemistry 20100615

• Young and older good learners have higher levels of brain nicotinic receptor binding.

  Neurobiology of aging 20100601

• Acetylcholinesterase inhibitors and memantine for neuroenhancement in healthy individuals: a systematic review.

  Pharmacological research 20100601

• Cognition-enhancing properties of Dimebon in a rat novel object recognition task are unlikely to be associated with acetylcholinesterase inhibition or N-methyl-D-aspartate receptor antagonism.

  The Journal of pharmacology and experimental therapeutics 20100601

• Entering and exiting the Medicare part D coverage gap: role of comorbidities and demographics.

  Journal of general internal medicine 20100601

• Cholinesterase inhibitors ameliorate spatial learning deficits in rats following hypobaric hypoxia.

  Experimental brain research 20100601

• [Acetylcholinesterase inhibitors in Alzheimer's disease: further comments on their mechanisms of action and therapeutic consequences].

  Psychologie & neuropsychiatrie du vieillissement 20100601

• The dramatic effects of Galantamine in a patient with early-onset Alzheimer's disease.

  Psychiatria Danubina 20100601

• [Oral galantamine versus rivastigmine transdermal patch: a descriptive study at a memory clinic in The Netherlands].

  Tijdschrift voor gerontologie en geriatrie 20100601

• Antiamnesic effect of stevioside in scopolamine-treated rats.

  Indian journal of pharmacology 20100601

• Semisynthesis and acetylcholinesterase inhibitory activity of stemofoline alkaloids and analogues.

  Journal of natural products 20100528

• Galantamine inhibits slowly inactivating K+ currents with a dual dose-response relationship in differentiated N1E-115 cells and in CA1 neurones.

  European journal of pharmacology 20100525

• Bivalent beta-carbolines as potential multitarget anti-Alzheimer agents.

  Journal of medicinal chemistry 20100513

• Total synthesis of (+/-)-galanthamine via a C3-selective Stille coupling and IMDA cycloaddition cascade of 3,5-dibromo-2-pyrone.

  Organic letters 20100507

• A review of clinical pharmacokinetics and pharmacodynamics of galantamine, a reversible acetylcholinesterase inhibitor for the treatment of Alzheimer's disease, in healthy subjects and patients.

  Current clinical pharmacology 20100501

• Behavioral side effects in rats treated with acetylcholinesterase inhibitors suggested used as prophylactics against nerve agents.

  Pharmacology, biochemistry, and behavior 20100501

• Bivalent 5,8,9,13b-tetrahydro-6H-isoquino[1,2-a]isoquinolines and -isoquinolinium salts: novel heterocyclic templates for butyrylcholinesterase inhibitors.

  Bioorganic & medicinal chemistry letters 20100501

• Anticholinesterase duration in the Australian veteran population.

  The Australian and New Zealand journal of psychiatry 20100501

• Alternative method of oral dosing for rats.

  Journal of the American Association for Laboratory Animal Science : JAALAS 20100501

• [Antianaphylactic effects of muscarinic antagonists].

  Eksperimental'naia i klinicheskaia farmakologiia 20100501

• [Variability and trends in dementia drug consumption in Castile-La Mancha (Spain). Estimated prevalence of Alzheimer's disease].

  Neurologia (Barcelona, Spain) 20100501

• In vitro biological activities of niloticane, a new bioactive cassane diterpene from the bark of Acacia nilotica subsp. kraussiana.

  Journal of ethnopharmacology 20100421

• Super-short solid silicon microneedles for transdermal drug delivery applications.

  International journal of pharmaceutics 20100415

• Acetylcholinesterase inhibitory potential of a carbazole alkaloid, mahanimbine, from Murraya koenigii.

  Phytotherapy research : PTR 20100401

• Cholinesterase inhibitors as adjunctive therapy in patients with schizophrenia and schizoaffective disorder: a review and meta-analysis of the literature.

  CNS drugs 20100401

• [Development of anti-Alzheimer's disease drug based on beta-amyloid hypothesis].

  Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan 20100401

• Nationwide drug-dispensing data reveal important differences in adherence to drug label recommendations on CYP2D6-dependent drug interactions.

  British journal of clinical pharmacology 20100401

• Calcium signaling and neurodegeneration.

  Acta naturae 20100401

• S 24795 limits beta-amyloid-alpha7 nicotinic receptor interaction and reduces Alzheimer's disease-like pathologies.

  Biological psychiatry 20100315

• Acetylcholinesterase inhibitors from the toadstool Cortinarius infractus.

  Bioorganic & medicinal chemistry 20100315

• Acetylcholinesterase enzyme inhibitory potential of standardized extract of Trigonella foenum graecum L and its constituents.

  Phytomedicine : international journal of phytotherapy and phytopharmacology 20100301

• Prescribing of drugs for Alzheimer's disease: a South African database analysis.

  International psychogeriatrics 20100301

• Galantamine for Alzheimer's disease.

  Expert opinion on drug metabolism & toxicology 20100301

• Reversible acetylcholinesterase inhibitory effect of Tabernaemontana divaricata extract on synaptic transmission in rat CA1 hippocampus.

  The Indian journal of medical research 20100301

• Update on the pharmacological treatment of Alzheimer's disease.

  Current neuropharmacology 20100301

• The ADAS-cog and clinically meaningful change in the VISTA clinical trial of galantamine for Alzheimer's disease.

  International journal of geriatric psychiatry 20100201

• Efficacy of SSRIs on cognition of Alzheimer's disease patients treated with cholinesterase inhibitors.

  International psychogeriatrics 20100201

• Increased glutamate in the hippocampus after galantamine treatment for Alzheimer disease.

  Progress in neuro-psychopharmacology & biological psychiatry 20100201

• [A negative first-line work-up of Raynaud's phenomenon: And what if it were cancer?].

  Journal des maladies vasculaires 20100201

• Synthesis, biological evaluation, and molecular modeling of berberine derivatives as potent acetylcholinesterase inhibitors.

  Bioorganic & medicinal chemistry 20100201

• Effects of donepezil, galantamine and rivastigmine in 938 Italian patients with Alzheimer's disease: a prospective, observational study.

  CNS drugs 20100201

• Acetylcholinesterases of the cat flea Ctenocephalides felis: identification of two distinct genes and biochemical characterization of recombinant and in vivo enzyme activities.

  Insect biochemistry and molecular biology 20100201

• Iron leads to memory impairment that is associated with a decrease in acetylcholinesterase pathways.

  Current neurovascular research 20100201

• Effects of cholinesterase inhibitors on the activities and protein levels of cholinesterases in the cerebrospinal fluid of patients with Alzheimer's disease: a review of recent clinical studies.

  Current Alzheimer research 20100201

• Galantamine does not cause aggravated orthostatic hypotension in people with Alzheimer's disease.

  Journal of the American Geriatrics Society 20100201

• Structural and functional neuroprotection in glaucoma: role of galantamine-mediated activation of muscarinic acetylcholine receptors.

  Cell death & disease 20100201

• Probing Torpedo californica acetylcholinesterase catalytic gorge with two novel bis-functional galanthamine derivatives.

  Journal of medicinal chemistry 20100128

• Memogain is a galantamine pro-drug having dramatically reduced adverse effects and enhanced efficacy.

  Journal of molecular neuroscience : MN 20100101

• The astrocyte-derived alpha7 nicotinic receptor antagonist kynurenic acid controls extracellular glutamate levels in the prefrontal cortex.

  Journal of molecular neuroscience : MN 20100101

• Molecular and cellular actions of galantamine: clinical implications for treatment of organophosphorus poisoning.

  Journal of molecular neuroscience : MN 20100101

• Mechanisms of neuroprotective effects of nicotine and acetylcholinesterase inhibitors: role of alpha4 and alpha7 receptors in neuroprotection.

  Journal of molecular neuroscience : MN 20100101

• Analysis of metabolic variation and galanthamine content in Narcissus bulbs by 1H NMR.

  Phytochemical analysis : PCA 20100101

• Metabolic profiling of bioactive Pancratium canariense extracts by GC-MS.

  Phytochemical analysis : PCA 20100101

• Magnetic resonance imaging reveals that galantamine prevents structural brain damage induced by an acute exposure of guinea pigs to soman.

  Neurotoxicology 20100101

• Promotion effect of norgalanthamine, a component of Crinum asiaticum, on hair growth.

  European journal of dermatology : EJD 20100101

• Synthesis, spectral characterization and biological evaluation of phosphorylated derivatives of galanthamine.

  European journal of medicinal chemistry 20100101

• Eight-year prescription trends of memantine and cholinesterase inhibitors among persons 65 years and older in Germany.

  International clinical psychopharmacology 20100101

• Factors associated with serious adverse reactions to cholinesterase inhibitors: a study of spontaneous reporting.

  CNS drugs 20100101

• New method for the study of Amaryllidaceae alkaloid biosynthesis using biotransformation of deuterium-labeled precursor in tissue cultures.

  Acta biochimica Polonica 20100101

• Switching from oral cholinesterase inhibitors to the rivastigmine transdermal patch.

  CNS neuroscience & therapeutics 20100101

• Cognitive enhancement as a pharmacotherapy target for stimulant addiction.

  Addiction (Abingdon, England) 20100101

• Identification of inhibitors of Plasmodium falciparum phosphoethanolamine methyltransferase using an enzyme-coupled transmethylation assay.

  BMC biochemistry 20100101

• Lycorine and its derivatives for anticancer drug design.

  Mini reviews in medicinal chemistry 20100101

• Neurochemical basis for symptomatic treatment of Alzheimer's disease.

  Neuropharmacology 20100101

• Promotion of the mind through exercise (PROMoTE): a proof-of-concept randomized controlled trial of aerobic exercise training in older adults with vascular cognitive impairment.

  BMC neurology 20100101

• Frontotemporal dementia and pharmacologic interventions.

  The Journal of neuropsychiatry and clinical neurosciences 20100101

• Galantamine-ER for the treatment of mild-to-moderate Alzheimer's disease.

  Clinical interventions in aging 20100101

• Cholinergic sensitivity of the developing bullfrog (Rana catesbeiana) does not explain vulnerability to chronic nicotine exposure.

  Advances in experimental medicine and biology 20100101

• Antidepressants are a rational complementary therapy for the treatment of Alzheimer's disease.

  Molecular neurodegeneration 20100101

• Effects of Ginkgo biloba in dementia: systematic review and meta-analysis.

  BMC geriatrics 20100101

• Lower Barthel Index scores predict less prescription of pharmacological therapy in elderly patients with Alzheimer disease.

  Dementia and geriatric cognitive disorders 20100101

• Important groups of alkaloids derived biosynthetically from phenylalanine and tyrosine. Preface.

  The Alkaloids. Chemistry and biology 20100101

• Galanthamine from Galanthus and other Amaryllidaceae--chemistry and biology based on traditional use.

  The Alkaloids. Chemistry and biology 20100101

• Galanthamine production by Leucojum aestivum cultures in vitro.

  The Alkaloids. Chemistry and biology 20100101

• New prospectives in the delivery of galantamine for elderly patients using the IntelliDrug intraoral device: in vivo animal studies.

  Current pharmaceutical design 20100101

• New lobane and cembrane diterpenes from two comorian soft corals.

  Marine drugs 20100101

• Should the ApoE genotype be a covariate for clinical trials in Alzheimer disease?

  Alzheimer's research & therapy 20100101

• In silico modeling of the specific inhibitory potential of thiophene-2,3-dihydro-1,5-benzothiazepine against BChE in the formation of beta-amyloid plaques associated with Alzheimer's disease.

  Theoretical biology & medical modelling 20100101

• Cortical oxygen supply during postural hypotension is further decreased in Alzheimer's disease, but unrelated to cholinesterase-inhibitor use.

  Journal of Alzheimer's disease : JAD 20100101

• Quantitative determination of Amaryllidaceae alkaloids from Galanthus reginae-olgae subsp. vernalis and in vitro activities relevant for neurodegenerative diseases.

  Pharmaceutical biology 20100101

• Novel therapeutic drugs for neuropsychiatric disorders.

  The open medicinal chemistry journal 20100101

• Compliance assessment of ambulatory Alzheimer patients to aid therapeutic decisions by healthcare professionals.

  BMC health services research 20100101

• Changes in apolar metabolites during in vitro organogenesis of Pancratium maritimum.

  Plant physiology and biochemistry : PPB 20100101

• Synthesis and antimicrobial, acetylcholinesterase and butyrylcholinesterase inhibitory activities of novel ester and hydrazide derivatives of 3(2H)-pyridazinone.

  Arzneimittel-Forschung 20100101

• The Nuclear Receptor PPARgamma as a Therapeutic Target for Cerebrovascular and Brain Dysfunction in Alzheimer's Disease.

  Frontiers in aging neuroscience 20100101

• Acetylcholinesterase inhibitory activity of uleine from Himatanthus lancifolius.

  Zeitschrift fur Naturforschung. C, Journal of biosciences 20100101

• Alkaloid accumulation in different parts and ages of Lycoris chinensis.

  Zeitschrift fur Naturforschung. C, Journal of biosciences 20100101

• [Anti-inflammatory role of cholinergic and serotonergic systems in shock].

  Patologicheskaia fiziologiia i eksperimental'naia terapiia 20100101

• Acetylcholinesterase Inhibitors (AChEI's) for the treatment of visual hallucinations in schizophrenia: a case report.

  BMC psychiatry 20100101

• Acetylcholinesterase Inhibitors (AChEI's) for the treatment of visual hallucinations in schizophrenia: a review of the literature.

  BMC psychiatry 20100101

• Are guidelines needed for the diagnosis and management of incipient Alzheimer's disease and mild cognitive impairment?

  International journal of Alzheimer's disease 20100101

• Circadian rhythm disturbances in patients with Alzheimer's disease: a review.

  International journal of Alzheimer's disease 20100101

• Targeting S100B in Cerebral Ischemia and in Alzheimer's Disease.

  Cardiovascular psychiatry and neurology 20100101

• Behavioural symptoms in patients with Alzheimer's disease and their association with cognitive impairment.

  BMC neurology 20100101

• Galantamine in the treatment of minor depression with mild to moderate Alzheimer's dementia in an elderly woman.

  Primary care companion to the Journal of clinical psychiatry 20100101

• A Quick Test of cognitive speed is sensitive in detecting early treatment response in Alzheimer's disease.

  Alzheimer's research & therapy 20100101

• Modelling the clinical and economic implications of galantamine in the treatment of mild-to-moderate Alzheimer's disease in Germany.

  Journal of medical economics 20100101

• Trace eyeblink conditioning is impaired in α7 but not in β2 nicotinic acetylcholine receptor knockout mice.

  Frontiers in behavioral neuroscience 20100101

• Effect of elevated intra-abdominal pressure on the contractile activity and reactivity of smooth muscle tissue from rat gastrointestinal tract to galantamine and drotaverine (No-Spa).

  Folia medica 20100101

• Effects of general practitioner training and family support services on the care of home-dwelling dementia patients--results of a controlled cluster-randomized study.

  BMC health services research 20100101

• A new strategy for antidepressant prescription.

  Frontiers in neuroscience 20100101

• Addressing the challenges to successful recruitment and retention in Alzheimer's disease clinical trials.

  Alzheimer's research & therapy 20100101

• Recent advances in the assessment and treatment of falls in Parkinson's disease.

  F1000 medicine reports 20100101

• Neuroinflammation Screening in Immunotherapy Trials against Alzheimer's Disease.

  International journal of Alzheimer's disease 20100101

• Brain imaging of nicotinic receptors in Alzheimer's disease.

  International journal of Alzheimer's disease 20100101

• The geriatric population and psychiatric medication.

  Mens sana monographs 20100101

• [Cholinesterase inhibitors for treating dementia. Review].

  Vertex (Buenos Aires, Argentina) 20100101

• Dementia.

  BMJ clinical evidence 20100101

• Traditional used Plants against Cognitive Decline and Alzheimer Disease.

  Frontiers in pharmacology 20100101

• The first phytochemical report of Galanthus transcaucasicus Fomin.

  Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences 20100101

• Acetylcholinesterase inhibition and insulin resistance in late onset Alzheimer's disease.

  International psychogeriatrics 20091201

• International price comparisons of Alzheimer's drugs: a way to close the affordability gap.

  International psychogeriatrics 20091201

• Effectiveness of donepezil, rivastigmine, and (+/-)huperzine A in counteracting the acute toxicity of organophosphorus nerve agents: comparison with galantamine.

  The Journal of pharmacology and experimental therapeutics 20091201

• Metabolic profiling of rat brain and cognitive behavioral tasks: potential complementary strategies in preclinical cognition enhancement research.

  Journal of proteome research 20091201

• Comparative effectiveness research: an approach to avoiding 'overgeneralized medicine'.

  Clinical and translational science 20091201

• Mechanisms of action of antipsychotic drugs of different classes, refractoriness to therapeutic effects of classical neuroleptics, and individual variation in sensitivity to their actions: Part I.

  Current neuropharmacology 20091201

• Concise syntheses of (-)-galanthamine and (+/-)-codeine via intramolecular alkylation of a phenol derivative.

  Journal of the American Chemical Society 20091111

• Structural model for the binding sites of allosterically potentiating ligands on nicotinic acetylcholine receptors.

  ChemMedChem 20091101

• Cholinesterase inhibitors and incidence of bradycardia in patients with dementia in the veterans affairs new England healthcare system.

  Journal of the American Geriatrics Society 20091101

• Packages of care for dementia in low- and middle-income countries.

  PLoS medicine 20091101

• Can we do better in developing new drugs for Alzheimer's disease?

  Alzheimer's & dementia : the journal of the Alzheimer's Association 20091101

• Alzheimer's disease: Seeing the signs early.

  Journal of the American Academy of Nurse Practitioners 20091101

• Cost-effectiveness: cholinesterase inhibitors and memantine in vascular dementia.

  The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques 20091101

• Cholinesterase inhibitory activities of some flavonoid derivatives and chosen xanthone and their molecular docking studies.

  Chemico-biological interactions 20091030

• Inhibition of human P-glycoprotein transport and substrate binding using a galantamine dimer.

  Biochemical and biophysical research communications 20091030

• Effects of galantamine on L-NAME-induced behavioral impairment in Y-maze task in mice.

  Neuroscience letters 20091025

• Galantamine is a novel post-exposure therapeutic against lethal VX challenge.

  Toxicology and applied pharmacology 20091015

• Acetylcholinesterase inhibitors enhance cognitive functions in rats following hypobaric hypoxia.

  Behavioural brain research 20091012

• Are cholinesterase inhibitors effective in the management of the behavioral and psychological symptoms of dementia in Alzheimer's disease? A systematic review of randomized, placebo-controlled trials of donepezil, rivastigmine and galantamine.

  International psychogeriatrics 20091001

• Trospium and cognition in patients with late onset Alzheimer disease.

  The journal of nutrition, health & aging 20091001

• Study of acetylcholinesterase inhibitors using CE with contactless conductivity detection.

  Electrophoresis 20091001

• Case report: combined use of donepezil and galantamine in mixed dementia.

  Journal of the American Geriatrics Society 20091001

• Galantamine enhancement of long-term potentiation is mediated by calcium/calmodulin-dependent protein kinase II and protein kinase C activation.

  Hippocampus 20090901

• Misplacing objects in mild to moderate Alzheimer's disease: a descriptive analysis from the VISTA clinical trial.

  Journal of neurology, neurosurgery, and psychiatry 20090901

• Nicotinic receptors: allosteric transitions and therapeutic targets in the nervous system.

  Nature reviews. Drug discovery 20090901

• Acetylcholinesterase inhibitive activity-guided isolation of two new alkaloids from seeds of Peganum nigellastrum Bunge by an in vitro TLC- bioautographic assay.

  Archives of pharmacal research 20090901

• Cholinesterase inhibitors and hospitalization for bradycardia: a population-based study.

  PLoS medicine 20090901

• The effects of galantamine hydrobromide treatment on dehydroepiandrosterone sulfate and cortisol levels in patients with chronic fatigue syndrome.

  Psychiatry investigation 20090901

• Neuroprotective effect of treatment with galantamine and choline alphoscerate on brain microanatomy in spontaneously hypertensive rats.

  Journal of the neurological sciences 20090815

• Magnesium effect on the acetylcholinesterase inhibition mechanism: a molecular chromatographic approach.

  Talanta 20090815

• Cholinesterase inhibitory effects of the extracts and compounds of Maclura pomifera (Rafin.) Schneider.

  Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association 20090801

• Baseline MRI predictors of conversion from MCI to probable AD in the ADNI cohort.

  Current Alzheimer research 20090801

• Treatment of mild cognitive impairment (MCI).

  Current Alzheimer research 20090801

• Validation of Abeta1-40 administration into mouse cerebroventricles as an animal model for Alzheimer disease.

  Brain research 20090714

• Protective effect of the ethanol extract of Magnolia officinalis and 4-O-methylhonokiol on scopolamine-induced memory impairment and the inhibition of acetylcholinesterase activity.

  Journal of natural medicines 20090701

• Cholinergic deficiency involved in vascular dementia: possible mechanism and strategy of treatment.

  Acta pharmacologica Sinica 20090701

• BZYX, a novel acetylcholinesterase inhibitor, significantly improved chemicals-induced learning and memory impairments on rodents and protected PC12 cells from apoptosis induced by hydrogen peroxide.

  European journal of pharmacology 20090624

• Selective cytochrome P450 3A4 inhibitory activity of Amaryllidaceae alkaloids.

  Bioorganic & medicinal chemistry letters 20090615

• Synthesis, biological evaluation and molecular modeling of oxoisoaporphine and oxoaporphine derivatives as new dual inhibitors of acetylcholinesterase/butyrylcholinesterase.

  European journal of medicinal chemistry 20090601

• Electroencephalographic effects of galantamine in major depressive disorder.

  Journal of clinical neurophysiology : official publication of the American Electroencephalographic Society 20090601

• A double-blind, placebo-controlled pilot study of galantamine to improve cognitive dysfunction in minimally symptomatic bipolar disorder.

  Journal of clinical psychopharmacology 20090601

• [From symptomatic to disease modifying therapy? Recent developments in the pharmacotherapy of Alzheimer's disease].

  Fortschritte der Neurologie-Psychiatrie 20090601

• Trends in the molecular pathogenesis and clinical therapeutics of common neurodegenerative disorders.

  International journal of molecular sciences 20090601

• Epidemiology of Alzheimer's disease: occurrence, determinants, and strategies toward intervention.

  Dialogues in clinical neuroscience 20090601

• Drug-induced sialorrhoea and excessive saliva accumulation.

  Prescrire international 20090601

• Cholinesterase based amperometric biosensors for assay of anticholinergic compounds.

  Interdisciplinary toxicology 20090601

• Galantamine inhibits beta-amyloid aggregation and cytotoxicity.

  Journal of the neurological sciences 20090515

• Treatment of Alzheimer's disease in the long-term-care setting.

  American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20090515

• Nefiracetam and galantamine modulation of excitatory and inhibitory synaptic transmission via stimulation of neuronal nicotinic acetylcholine receptors in rat cortical neurons.

  Neuroscience 20090505

• Treatment with galantamine and time to nursing home placement in Alzheimer's disease patients with and without cerebrovascular disease.

  International journal of geriatric psychiatry 20090501

• Pharmacokinetics of a novel transdermal rivastigmine patch for the treatment of Alzheimer's disease: a review.

  International journal of clinical practice 20090501

• Cholinesterase inhibitors and beyond.

  Current Alzheimer research 20090401

• Decreased activation along the dorsal visual pathway after a 3-month treatment with galantamine in mild Alzheimer disease: a functional magnetic resonance imaging study.

  Journal of clinical psychopharmacology 20090401

• Antioxidant and anticholinesterase activity evaluation of ent-kaurane diterpenoids from Sideritis arguta.

  Journal of natural products 20090327

• Two-dimensional turbulent flow chromatography coupled on-line to liquid chromatography-mass spectrometry for solution-based ligand screening against multiple proteins.

  Journal of chromatography. A 20090320

• Highly efficient, selective and sensitive molecular screening of acetylcholinesterase inhibitors of natural origin by solid-phase extraction-liquid chromatography/electrospray ionisation-octopole-orthogonal acceleration time-of-flight-mass spectrometry and novel thin-layer chromatography-based bioautography.

  Journal of chromatography. A 20090320

• Effect of R3487/MEM3454, a novel nicotinic alpha7 receptor partial agonist and 5-HT3 antagonist on sustained attention in rats.

  Progress in neuro-psychopharmacology & biological psychiatry 20090317

• Acteylcholinesterase inhibitor rivastigmine enhances cellular defenses in neuronal and macrophage-like cell lines.

  Translational research : the journal of laboratory and clinical medicine 20090301

• Roles of nicotinic receptors in acetylcholinesterase inhibitor-induced neuroprotection and nicotinic receptor up-regulation.

  Biological & pharmaceutical bulletin 20090301

• Nicotinic receptor-mediated neuroprotection in neurodegenerative disease models.

  Biological & pharmaceutical bulletin 20090301

• Side effects of approved antidementives.

  Psychiatria Danubina 20090301

• An unusual case of nightmares with galantamine.

  Journal of the American Geriatrics Society 20090301

• Characteristic effects of anti-dementia drugs on rat sleep patterns.

  Journal of pharmacological sciences 20090301

• Bullous pemphigoid precipitated by galantamine hydrobromide.

  Cutis 20090301

• Alkaloid synthesis and accumulation in Leucojum aestivum in vitro cultures.

  Natural product communications 20090301

• Safety and tolerability of galantamine in possible Alzheimer's disease with or without cerebrovascular disease and vascular dementia in Thai patients.

  Journal of the Medical Association of Thailand = Chotmaihet thangphaet 20090301

• Effects of cholinesterase inhibition on brain white matter volume in Alzheimer's disease.

  Neuroreport 20090218

• Effects of memantine and galantamine given separately or in association, on memory and hippocampal neuronal loss after transient global cerebral ischemia in gerbils.

  Brain research 20090213

• Pressurized liquid extraction and anticholinesterase activity-based thin-layer chromatography with bioautography of Amaryllidaceae alkaloids.

  Analytica chimica acta 20090209

• Benzofurans as efficient dienophiles in normal electron demand [4 + 2] cycloadditions.

  The Journal of organic chemistry 20090206

• Design, synthesis and evaluation of galanthamine derivatives as acetylcholinesterase inhibitors.

  European journal of medicinal chemistry 20090201

• Early postnatal maternal deprivation in rats induces memory deficits in adult life that can be reversed by donepezil and galantamine.

  International journal of developmental neuroscience : the official journal of the International Society for Developmental Neuroscience 20090201

• Cholinergic modulation of the cerebral metabolic response to citalopram in Alzheimer's disease.

  Brain : a journal of neurology 20090201

• Simultaneous determination of galantamine, rivastigmine and NAP 226-90 in plasma by MEKC and its application in Alzheimer's disease.

  Electrophoresis 20090201

• Different cholinesterase inhibitor effects on CSF cholinesterases in Alzheimer patients.

  Current Alzheimer research 20090201

• Adherence to cholinesterase inhibitors in patients with Alzheimer's disease.

  Journal of the American Geriatrics Society 20090201

• Galantamine protects against oxidative stress induced by amyloid-beta peptide in cortical neurons.

  The European journal of neuroscience 20090201

• [Effects of anti-dementia drugs on sleep-wake patterns in sleep-disturbed rats].

  Nihon shinkei seishin yakurigaku zasshi = Japanese journal of psychopharmacology 20090201

• Galantamine for dementia in people with Down syndrome.

  The Cochrane database of systematic reviews 20090121

• Analyses of mortality risk in patients with dementia treated with galantamine.

  Acta neurologica Scandinavica 20090101

• Brain acetylcholinesterase activity controls systemic cytokine levels through the cholinergic anti-inflammatory pathway.

  Brain, behavior, and immunity 20090101

• Recent advances in treating cognitive impairment in schizophrenia.

  Psychopharmacology 20090101

• A single in vivo application of cholinesterase inhibitors has neuron type-specific effects on nicotinic receptor activity in guinea pig hippocampus.

  The Journal of pharmacology and experimental therapeutics 20090101

• A double-blind comparison of galantamine hydrobromide ER and placebo in Parkinson disease.

  Journal of neurology, neurosurgery, and psychiatry 20090101

• Galantamine-induced improvements in cognitive function are not related to alterations in alpha(4)beta (2) nicotinic receptors in early Alzheimer's disease as measured in vivo by 2-[18F]fluoro-A-85380 PET.

  Psychopharmacology 20090101

• The effects of galantamine on psychopathology in chronic stable schizophrenia.

  Clinical neuropharmacology 20090101

• [Relation between Pisa syndrome and choline esterase inhibitors in a cohort of Alzheimer's disease patients].

  Presse medicale (Paris, France : 1983) 20090101

• The SERAD study of the safety and efficacy of galantamine in severe Alzheimer's disease.

  The Lancet. Neurology 20090101

• Safety and efficacy of galantamine (Reminyl) in severe Alzheimer's disease (the SERAD study): a randomised, placebo-controlled, double-blind trial.

  The Lancet. Neurology 20090101

• Memoquin: a multi-target-directed ligand as an innovative therapeutic opportunity for Alzheimer's disease.

  Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics 20090101

• LCMS and GCMS for the screening of alkaloids in natural and in vitro extracts of Leucojum aestivum.

  Journal of natural products 20090101

• Galantamine improves apomorphine-induced deficits in prepulse inhibition via muscarinic ACh receptors in mice.

  British journal of pharmacology 20090101

• Pharmacological interventions in primary care: hopes and illusions.

  Frontiers of neurology and neuroscience 20090101

• Is it possible to treat vascular dementia?

  Frontiers of neurology and neuroscience 20090101

• Clinical features and diagnosis of frontotemporal dementia.

  Frontiers of neurology and neuroscience 20090101

• Selective and irreversible inhibitors of aphid acetylcholinesterases: steps toward human-safe insecticides.

  PloS one 20090101

• Changes in cognitive domains during three years in patients with Alzheimer's disease treated with donepezil.

  BMC neurology 20090101

• Effects of Subchronic Phencyclidine (PCP) Treatment on Social Behaviors, and Operant Discrimination and Reversal Learning in C57BL/6J Mice.

  Frontiers in behavioral neuroscience 20090101

• Inhibitory potency of choline esterase inhibitors on acetylcholine release and choline esterase activity in fresh specimens of human and rat neocortex.

  Journal of Alzheimer's disease : JAD 20090101

• Upregulation of alpha7 Nicotinic Receptors by Acetylcholinesterase C-Terminal Peptides.

  PloS one 20090101

• Carotid intima-media thickness as a predictor of response to cholinesterase inhibitors in Alzheimer's disease: an open-label trial.

  CNS drugs 20090101

• Cloning and heterologous expression of a new 3'-hydroxylase gene from Lycoris radiata.

  Zeitschrift fur Naturforschung. C, Journal of biosciences 20090101

• Early and differential diagnosis of dementia and mild cognitive impairment: design and cohort baseline characteristics of the German Dementia Competence Network.

  Dementia and geriatric cognitive disorders 20090101

• Optimal dosing of galantamine in patients with mild or moderate Alzheimer's disease: post Hoc analysis of a randomized, double-blind, placebo-controlled trial.

  Drugs & aging 20090101

• Novel regimens and delivery systems in the pharmacological treatment of Alzheimer's disease.

  CNS drugs 20090101

• Pharmacological Treatment of Alzheimer's Disease: Is it Progressing Adequately?

  The open neurology journal 20090101

• Verbal repetition in people with mild-to-moderate Alzheimer Disease: a descriptive analysis from the VISTA clinical trial.

  Alzheimer disease and associated disorders 20090101

• Dementia care initiative in primary practice: study protocol of a cluster randomized trial on dementia management in a general practice setting.

  BMC health services research 20090101

• Synthesis and characterization of new galanthamine derivatives comprising peptide moiety.

  Protein and peptide letters 20090101

• Optimized nutrient medium for galanthamine production in Leucojum aestivum L. in vitro shoot system.

  Zeitschrift fur Naturforschung. C, Journal of biosciences 20090101

• Persistence with cholinesterase inhibitor therapy for dementia: an observational administrative health database study.

  Drugs & aging 20090101

• Update on the use of memantine in Alzheimer's disease.

  Neuropsychiatric disease and treatment 20090101

• DOMINO-AD protocol: donepezil and memantine in moderate to severe Alzheimer's disease - a multicentre RCT.

  Trials 20090101

• Study of the ketogenic agent AC-1202 in mild to moderate Alzheimer's disease: a randomized, double-blind, placebo-controlled, multicenter trial.

  Nutrition & metabolism 20090101

• [Galantamine (reminyl) in the treatment of severe Alzheimer's disease].

  Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova 20090101

• Can cognitive enhancers reduce the risk of falls in older people with mild cognitive impairment? A protocol for a randomised controlled double blind trial.

  BMC neurology 20090101

• Quality of life as an outcome in Alzheimer's disease and other dementias--obstacles and goals.

  BMC neurology 20090101

• Emerging role of Garcinol, the antioxidant chalcone from Garcinia indica Choisy and its synthetic analogs.

  Journal of hematology & oncology 20090101

• Current treatments of Alzheimer disease: are main caregivers satisfied with the drug treatments received by their patients?

  Dementia and geriatric cognitive disorders 20090101

• The prevention and treatment of cognitive decline and dementia: An overview of recent research on experimental treatments.

  Indian journal of psychiatry 20090101

• Effect of abiotic and biotic elicitors on growth and alkaloid accumulation of Lycoris chinensis seedlings.

  Zeitschrift fur Naturforschung. C, Journal of biosciences 20090101

• Variants of ESR1, APOE, LPL and IL-6 loci in young healthy subjects: association with lipid status and obesity.

  BMC research notes 20090101

• Valproate-induced delirium in a demented patient.

  Archives of gerontology and geriatrics 20090101

• Persistent treatment with cholinesterase inhibitors and/or memantine slows clinical progression of Alzheimer disease.

  Alzheimer's research & therapy 20090101

• Galantamine-ER for cognitive dysfunction in bipolar disorder and correlation with hippocampal neuronal viability: a proof-of-concept study.

  CNS neuroscience & therapeutics 20090101

• Safety and tolerability of donepezil, rivastigmine and galantamine for patients with Alzheimer's disease: systematic review of the 'real-world' evidence.

  Dementia and geriatric cognitive disorders 20090101

• [The use of reminyl (galantamine) in the treatment of probable vascular dementia].

  Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova 20090101

• [The use of galantamine in Alzheimer's disease associated with vascular dementia (according to the study of T. Erkinjuntti group)].

  Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova 20090101

• Have last-observation-carried-forward analyses caused us to favour more toxic dementia therapies over less toxic alternatives? A systematic review.

  Open medicine : a peer-reviewed, independent, open-access journal 20090101

• Support for a tax increase to provide unrestricted access to an Alzheimer's disease medication: a survey of the general public in Canada.

  BMC health services research 20090101

• Current perspectives in the treatment of resistant schizophrenia.

  Indian journal of psychiatry 20090101

• Clinical practice with antidementia and antipsychotic drugs: Audit from a geriatric clinic in India.

  Indian journal of psychiatry 20090101

• Pharmacokinetic Study of a Novel Antihyperlipidemic Agent LM-13765- A Prodrug.

  Indian journal of pharmaceutical sciences 20090101

• Modeling the cost-effectiveness of galantamine for mild to moderately severe Alzheimer's disease in Korea.

  Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research 20090101

• Mild cognitive impairment: The dilemma.

  Indian journal of psychiatry 20090101

• Vascular cognitive impairment.

  Indian journal of psychiatry 20090101

• Frontotemporal dementia: An updated overview.

  Indian journal of psychiatry 20090101

• Memory clinics in context.

  Indian journal of psychiatry 20090101

• Behavioral and psychological symptoms of dementia and their management.

  Indian journal of psychiatry 20090101

• Safety and efficacy of antipsychotic drugs for the behavioral and psychological symptoms of dementia.

  Indian journal of psychiatry 20090101

• Screening the methanol extracts of some Iranian plants for acetylcholinesterase inhibitory activity.

  Research in pharmaceutical sciences 20090101

• Galantamine reduces striatal degeneration in 3-nitropropionic acid model of Huntington's disease.

  Neuroscience letters 20081219

• Association mechanism of four acetylcholinesterase inhibitors (AChEIs) with human serum albumin: a biochromatographic approach.

  Journal of pharmaceutical and biomedical analysis 20081215

• Longitudinal multimodal imaging in mild to moderate Alzheimer disease: a pilot study with memantine.

  Journal of neurology, neurosurgery, and psychiatry 20081201

• Monitoring enzyme reaction and screening of inhibitors of acetylcholinesterase by quantitative matrix-assisted laser desorption/ionization Fourier transform mass spectrometry.

  Journal of the American Society for Mass Spectrometry 20081201

• Synergistic effect of galantamine on nicotine-induced neuroprotection in hemiparkinsonian rat model.

  Neuroscience research 20081201

• Galantamine for the treatment of BPSD in Thai patients with possible Alzheimer's disease with or without cerebrovascular disease.

  American journal of Alzheimer's disease and other dementias 20081201

• Importance of circadian rhythmicity in the cholinergic treatment of Alzheimer's disease: focus on galantamine*.

  Current medical research and opinion 20081201

• Efficacy of a vitamin/nutriceutical formulation for early-stage Alzheimer's disease: a 1-year, open-label pilot study with an 16-month caregiver extension.

  American journal of Alzheimer's disease and other dementias 20081201

• Acetylcholinesterase-inhibiting activity of pyrrole derivatives from a novel marine gliding bacterium, Rapidithrix thailandica.

  Marine drugs 20081201

• Impact of cholinesterase inhibitors on behavioral and psychological symptoms of Alzheimer's disease: a meta-analysis.

  Clinical interventions in aging 20081201

• Effects of cholinotropic and cytostatic drugs on the development of Arthus reaction.

  Bulletin of experimental biology and medicine 20081201

• Quantitation of donepezil and its active metabolite 6-O-desmethyl donepezil in human plasma by a selective and sensitive liquid chromatography-tandem mass spectrometric method.

  Analytica chimica acta 20081123

• Nicotinic acetylcholine receptors and modulation of learning in 4- and 27-month-old rabbits.

  Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 20081101

• Evaluation of galantamine transbuccal absorption by reconstituted human oral epithelium and porcine tissue as buccal mucosa models: part I.

  European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V 20081101

• Efficacy and safety of galantamine (reminyl) for dementia in patients with Parkinson's disease (an open controlled trial).

  Neuroscience and behavioral physiology 20081101

• [Bradycardia induced by galantamine].

  Annales francaises d'anesthesie et de reanimation 20081101

• Vesicular acetylcholine transporter (VAChT) in the brain of spontaneously hypertensive rats (SHR): effect of treatment with an acetylcholinesterase inhibitor.

  Clinical and experimental hypertension (New York, N.Y. : 1993) 20081101

• Relative tolerability of Alzheimer's disease treatments.

  Psychiatry (Edgmont (Pa. : Township)) 20081101

• Domino double Michael-Claisen cyclizations: a powerful general tool for introducing quaternary stereocenters at C4 of cyclohexane-1,3-diones and total synthesis of diverse families of sterically congested alkaloids.

  The Journal of organic chemistry 20081003

• Decreased initiation of usual activities in people with mild-to-moderate Alzheimer's disease: a descriptive analysis from the VISTA clinical trial.

  International psychogeriatrics 20081001

• Effects of 5-HT6 receptor antagonism and cholinesterase inhibition in models of cognitive impairment in the rat.

  British journal of pharmacology 20081001

• Effects of cholinesterase inhibitors on rat nicotinic receptor levels in vivo and in vitro.

  Journal of neural transmission (Vienna, Austria : 1996) 20081001

• Diagnosis and management of Parkinson's disease dementia.

  International journal of clinical practice 20081001

• Errorless learning and spaced retrieval techniques to relearn instrumental activities of daily living in mild Alzheimer's disease: A case report study.

  Neuropsychiatric disease and treatment 20081001

• Neuropharmacology.

  Indian journal of pharmacology 20081001

• Flexibility versus 'rigidity' of the functional architecture of AChE active center.

  Chemico-biological interactions 20080925

• Study of neuroprotection of donepezil, a therapy for Alzheimer's disease.

  Chemico-biological interactions 20080925

• Anti-acetylcholinesterase activities of traditional Chinese medicine for treating Alzheimer's disease.

  Chemico-biological interactions 20080925

• Galantamine treatment in Alzheimer's disease with cerebrovascular disease: responder analyses from a randomized, controlled trial (GAL-INT-6).

  Journal of psychopharmacology (Oxford, England) 20080901

• Adjunctive galantamine, but not donepezil, enhances the antipsychotic-like effect of raclopride in rats.

  The international journal of neuropsychopharmacology 20080901

• An open-label pilot study of acetylcholinesterase inhibitors to promote functional recovery in elderly cognitively impaired stroke patients.

  Cerebrovascular diseases (Basel, Switzerland) 20080901

• Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial.

  The Lancet. Neurology 20080901

• Spinal p38 MAP kinase regulates peripheral cholinergic outflow.

  Arthritis and rheumatism 20080901

• [Galantamine].

  Revue de l'infirmiere 20080901

• [Galantamine therapy in dementia associated with CADASIL].

  Revista de neurologia 20080901

• The effect of Galantamine on sleep quality in Thai Alzheimer's disease patients.

  Journal of the Medical Association of Thailand = Chotmaihet thangphaet 20080901

• Drug utilization review of cholinesterase inhibitors in Quebec.

  The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques 20080901

• Role of the central cholinergic system in the therapeutics of schizophrenia.

  Current neuropharmacology 20080901

• Solid-phase synthesis and biological evaluation of a parallel library of 2,3-dihydro-1,5-benzothiazepines.

  Bioorganic & medicinal chemistry 20080815

• PET imaging of the in vivo brain acetylcholinesterase activity and nicotine binding in galantamine-treated patients with AD.

  Neurobiology of aging 20080801

• Lack of beneficial galantamine effect for smoking behavior: a double-blind randomized trial in people with schizophrenia.

  Schizophrenia research 20080801

• The safety and tolerability of galantamine in patients with epilepsy and memory difficulties.

  Epilepsy & behavior : E&B 20080801

• Effects of galantamine on cognitive deficits in smokers and non-smokers with schizophrenia.

  Schizophrenia research 20080801

• Natural products as an inspiration in the diversity-oriented synthesis of bioactive compound libraries.

  Natural product reports 20080801

• A nonlinear mixed effects IVIVC model for multi-release drug delivery systems.

  Journal of pharmacokinetics and pharmacodynamics 20080801

• Rivastigmine transdermal patch: role in the management of Alzheimer's disease.

  The Consultant pharmacist : the journal of the American Society of Consultant Pharmacists 20080801

• The effects of rivastigmine plus selegiline on brain acetylcholinesterase, (Na, K)-, Mg-ATPase activities, antioxidant status, and learning performance of aged rats.

  Neuropsychiatric disease and treatment 20080801

• Current approaches to the treatment of Parkinson's disease.

  Neuropsychiatric disease and treatment 20080801

• Present and prospective clinical therapeutic regimens for Alzheimer's disease.

  Neuropsychiatric disease and treatment 20080801

• Psychiatric disorders and traumatic brain injury.

  Neuropsychiatric disease and treatment 20080801

• Extracts and constituents of Leontopodium alpinum enhance cholinergic transmission: brain ACh increasing and memory improving properties.

  Biochemical pharmacology 20080715

• High-dose galantamine augmentation inferior to placebo on attention, inhibitory control and working memory performance in nonsmokers with schizophrenia.

  Schizophrenia research 20080701

• Roles of accessory subunits in alpha4beta2(*) nicotinic receptors.

  Molecular pharmacology 20080701

• Prevalence of cholinesterase inhibitors in subjects with dementia in Europe.

  Pharmacoepidemiology and drug safety 20080701

• Petrosamine, a potent anticholinesterase pyridoacridine alkaloid from a Thai marine sponge Petrosia n. sp.

  Bioorganic & medicinal chemistry 20080701

• Cholinergic treatments with emphasis on m1 muscarinic agonists as potential disease-modifying agents for Alzheimer's disease.

  Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics 20080701

• Exploiting protein fluctuations at the active-site gorge of human cholinesterases: further optimization of the design strategy to develop extremely potent inhibitors.

  Journal of medicinal chemistry 20080612

• The impact of galantamine on cognition and mood during electroconvulsive therapy: a pilot study.

  Journal of psychiatric research 20080601

• A double blind, placebo-controlled pilot study of galantamine augmentation of antidepressant treatment in older adults with major depression.

  International journal of geriatric psychiatry 20080601

• Galantamine as an adjunctive treatment in major depression.

  Journal of clinical psychopharmacology 20080601

• Hydrogen-bonding properties of galanthamine: an investigation through crystallographic database observations and computational chemistry.

  Acta crystallographica. Section B, Structural science 20080601

• Galantamine-induced pisa syndrome: memantine as an alternative.

  International journal of geriatric psychiatry 20080601

• Butyrylcholinesterase, lipoxygenase inhibiting and antifungal alkaloids from Isatis tinctoria.

  Journal of enzyme inhibition and medicinal chemistry 20080601

• Comparison of cholinesterase inhibitor utilization patterns and associated health care costs in Alzheimer's disease.

  Journal of managed care pharmacy : JMCP 20080601

• Cost-effectiveness of drug therapies for Alzheimer's disease: A brief review.

  Neuropsychiatric disease and treatment 20080601

• Safety and efficacy of galantamine in subjects with mild cognitive impairment.

  Neurology 20080527

• Treatment for MCI: is the evidence sufficient?

  Neurology 20080527

• Dementia medications in palliative care #174.

  Journal of palliative medicine 20080501

• Galantamine improves gait performance in patients with Alzheimer's disease.

  Journal of the American Geriatrics Society 20080501

• [Treatment of Alzheimer's disease: status quo and future considerations].

  Nihon yakurigaku zasshi. Folia pharmacologica Japonica 20080501

• Diagnosis and treatment of dementia with Lewy bodies.

  JAAPA : official journal of the American Academy of Physician Assistants 20080501

• 3-(3-Chloro-prop-yl)-7,8-dimeth-oxy-2,3,4,5-tetra-hydro-1H-3-benzazepin-2-one at 125 K.

  Acta crystallographica. Section E, Structure reports online 20080501

• 3-(3-Chloro-prop-yl)-7,8-dimeth-oxy-1H-3-benzazepin-2(3H)-one at 125 K.

  Acta crystallographica. Section E, Structure reports online 20080501

• Design, synthesis and pharmacological evaluation of hybrid molecules out of quinazolinimines and lipoic acid lead to highly potent and selective butyrylcholinesterase inhibitors with antioxidant properties.

  Bioorganic & medicinal chemistry 20080415

• AAFP and ACP release guideline on dementia treatment.

  American family physician 20080415

• For debate: is the evidence for the efficacy of cholinesterase inhibitors in the symptomatic treatment of Alzheimer's disease convincing or not?

  International psychogeriatrics 20080401

• Inhibition of cholinesterase and amyloid-beta aggregation by resveratrol oligomers from Vitis amurensis.

  Phytotherapy research : PTR 20080401

• N-Alkylated galanthamine derivatives: Potent acetylcholinesterase inhibitors from Leucojum aestivum.

  Bioorganic & medicinal chemistry letters 20080401

• [Treatment pattern of Alzheimer's disease with cholinesterase inhibitors (TRAIN study)].

  Revista de neurologia 20080401

• Prolonged cholinergic enrichment influences regional cortical activation in early Alzheimer's disease.

  Neuropsychiatric disease and treatment 20080401

• Galantamine and carbon monoxide protect brain microvascular endothelial cells by heme oxygenase-1 induction.

  Biochemical and biophysical research communications 20080314

• Summaries for patients. Drug treatment for patients with dementia: American College of Physicians and American Academy of Family Physicians recommendations.

  Annals of internal medicine 20080304

• Current pharmacologic treatment of dementia: a clinical practice guideline from the American College of Physicians and the American Academy of Family Physicians.

  Annals of internal medicine 20080304

• Effectiveness of cholinesterase inhibitors and memantine for treating dementia: evidence review for a clinical practice guideline.

  Annals of internal medicine 20080304

• The partial alpha7 nicotine acetylcholine receptor agonist S 24795 enhances long-term potentiation at CA3-CA1 synapses in the adult mouse hippocampus.

  Neuropharmacology 20080301

• Antioxidative properties of galantamine on neuronal damage induced by hydrogen peroxide in SK-N-SH cells.

  Neurotoxicology 20080301

• [Antidementia drugs--response or non-response?].

  Der Internist 20080301

• How long can patients with mild or moderate Alzheimer's dementia maintain both the cognition and the therapy of cholinesterase inhibitors: a national population-based study.

  European journal of neurology 20080301

• Pharmacodynamics of memantine: an update.

  Current neuropharmacology 20080301

• Inhibition of acetylcholinesterase in CSF versus brain assessed by 11C-PMP PET in AD patients treated with galantamine.

  Neurobiology of aging 20080201

• Omega-3 supplementation in mild to moderate Alzheimer's disease: effects on neuropsychiatric symptoms.

  International journal of geriatric psychiatry 20080201

• A randomised double-blind placebo-controlled trial of folic acid supplementation of cholinesterase inhibitors in Alzheimer's disease.

  International journal of geriatric psychiatry 20080201

• Patterns of decline and evidence of subgroups in patients with Alzheimer's disease taking galantamine for up to 48 months.

  International journal of geriatric psychiatry 20080201

• Effects of CDP-choline and the combination of CDP-choline and galantamine differ in an animal model of schizophrenia: development of a selective alpha7 nicotinic acetylcholine receptor agonist strategy.

  European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology 20080201

• Acetylcholinesterase inhibitors in assisted living: patterns of use and association with retention.

  International journal of geriatric psychiatry 20080201

• Galantamine and donepezil differently affect isolation rearing-induced deficits of prepulse inhibition in mice.

  Psychopharmacology 20080201

• Prolonged QT interval, syncope, and delirium with galantamine.

  The Annals of pharmacotherapy 20080201

• Neurotrophic factors in Alzheimer's disease: role of axonal transport.

  Genes, brain, and behavior 20080201

• Memantine treatment in patients with mild to moderate Alzheimer's disease already receiving a cholinesterase inhibitor: a randomized, double-blind, placebo-controlled trial.

  Current Alzheimer research 20080201

• Economic and clinical benefits of galantamine in the treatment of mild to moderate Alzheimer's disease in a Korean population: a 52-week prospective study.

  Journal of Korean medical science 20080201

• Pharmacologic management of Alzheimer disease.

  The Journal of neuroscience nursing : journal of the American Association of Neuroscience Nurses 20080201

• The mechanisms of neurodegenerative processes and current pharmacotherapy of Alzheimer's disease.

  Georgian medical news 20080201

• [Cholinesterase inhibitors in the treatment of dementia--are they useful in clinical practice?].

  Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke 20080131

• Cholinesterase inhibitors for delirium.

  The Cochrane database of systematic reviews 20080123

• [Therapy of cognitive deficits in schizophrenia with acetylcholinesterase inhibitors. A systematic overview].

  Der Nervenarzt 20080101

• Galantamine for the treatment of cognitive impairments in people with schizophrenia.

  The American journal of psychiatry 20080101

• Education and use of dementia drugs: a register-based study of over 600,000 older people.

  Dementia and geriatric cognitive disorders 20080101

• Galantamine in Alzheimer's disease.

  Expert review of neurotherapeutics 20080101

• Rapid cognitive improvement in Alzheimer's disease following perispinal etanercept administration.

  Journal of neuroinflammation 20080101

• Galantamine in frontotemporal dementia and primary progressive aphasia.

  Dementia and geriatric cognitive disorders 20080101

• Gliomatosis cerebri presenting as rapidly progressive dementia and parkinsonism in an elderly woman: a case report.

  Journal of medical case reports 20080101

• First administration of cytidine diphosphocholine and galantamine in schizophrenia: a sustained alpha7 nicotinic agonist strategy.

  Clinical neuropharmacology 20080101

• Effects of galantamine on measures of attention: results from 2 clinical trials in Alzheimer disease patients with comparisons to donepezil.

  Alzheimer disease and associated disorders 20080101

• Pharmacogenomics in Alzheimer's disease.

  Methods in molecular biology (Clifton, N.J.) 20080101

• [Treatment of Alzheimer's Disease cognitive symptoms].

  Vertex (Buenos Aires, Argentina) 20080101

• Analysis of galanthamine-type alkaloids by capillary gas chromatography-mass spectrometry in plants.

  Phytochemical analysis : PCA 20080101

• New rapid validated HPTLC method for the determination of galanthamine in Amaryllidaceae plant extracts.

  Phytochemical analysis : PCA 20080101

• Rapid TLC/GC-MS identification of acetylcholinesterase inhibitors in alkaloid extracts.

  Phytochemical analysis : PCA 20080101

• Healthcare costs and utilization for Medicare beneficiaries with Alzheimer's.

  BMC health services research 20080101

• Variability in the diagnosis and management of patients with Alzheimer's disease and cerebrovascular disease: results from the GALATEA multicentre, observational study.

  Clinical drug investigation 20080101

• The clinical significance of plasmatic amyloid A{beta}-40 peptide levels in Alzheimer's disease patients treated with galantamine.

  American journal of Alzheimer's disease and other dementias 20080101

• One-week dose titration of extended release galantamine in patients with Alzheimer's disease.

  Alzheimer's & dementia : the journal of the Alzheimer's Association 20080101

• Review of issue: studies on veterans, a useful pain scale, and plasma amyloid levels as a predictor of response to medications.

  American journal of Alzheimer's disease and other dementias 20080101

• [Combined use of reminyl (galanthamine) and ovestin (oestradiol) for the treatment of cognitive disorders in women with hypoestrogenic syndrome].

  Eksperimental'naia i klinicheskaia farmakologiia 20080101

• Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer's disease: a systematic review and meta-analysis.

  Clinical interventions in aging 20080101

• Combined models for data from in vitro-in vivo correlation experiments.

  Journal of biopharmaceutical statistics 20080101

• The therapeutical potential of alpha-synuclein antiaggregatory agents for dementia with Lewy bodies.

  Current medicinal chemistry 20080101

• Neurological and psychiatric practitioners' views on Alzheimer's disease and treatment thereof.

  Dementia and geriatric cognitive disorders 20080101

• Genomic NGFB variation and multiple sclerosis in a case control study.

  BMC medical genetics 20080101

• Intranasal delivery bypasses the blood-brain barrier to target therapeutic agents to the central nervous system and treat neurodegenerative disease.

  BMC neuroscience 20080101

• Intranasal administration of acetylcholinesterase inhibitors.

  BMC neuroscience 20080101

• Electrically enhanced and controlled drug delivery through buccal mucosa.

  Acta poloniae pharmaceutica 20080101

• Discontinuing Alzheimer's disease drug therapy: why, when, and how.

  Director (Cincinnati, Ohio) 20080101

• Chronic fatigue syndrome.

  BMJ clinical evidence 20080101

• Once-daily transdermal rivastigmine in the treatment of Alzheimer's disease.

  Drug design, development and therapy 20080101

• Comparison of persistence rates of acetylcholine-esterase inhibitors in a state Medicaid program.

  Patient preference and adherence 20080101

• Neuroinflammation and tumor necrosis factor signaling in the pathophysiology of Alzheimer's disease.

  Journal of inflammation research 20080101

• Influence of galantamine on vasomotor reactivity in Alzheimer's disease and vascular dementia due to cerebral microangiopathy.

  Stroke 20071201

• An update on the pharmacology of galantamine.

  Expert opinion on investigational drugs 20071201

• Risperidone, olanzapine and quetiapine in the treatment of behavioral and psychological symptoms in patients with Alzheimer's disease: preliminary findings from a naturalistic, retrospective study.

  Psychiatry and clinical neurosciences 20071201

• Management of the behavioral and psychological symptoms of dementia.

  Clinical interventions in aging 20071201

• The challenge of supporting care for dementia in primary care.

  Clinical interventions in aging 20071201

• Rivastigmine in Alzheimer's disease: Cognitive function and quality of life.

  Therapeutics and clinical risk management 20071201

• Rivastigmine for the treatment of dementia associated with Parkinson's disease.

  Neuropsychiatric disease and treatment 20071201

• Rivastigmine in Chinese patients with subcortical vascular dementia.

  Neuropsychiatric disease and treatment 20071201

• Anti-inflammatory and immune therapy for Alzheimer's disease: current status and future directions.

  Current neuropharmacology 20071201

• Current therapeutic options for Alzheimer's disease.

  Current genomics 20071201

• New potent acetylcholinesterase inhibitors in the tetracyclic triterpene series.

  Journal of medicinal chemistry 20071101

• Cholinesterase inhibitors in mild cognitive impairment: a systematic review of randomised trials.

  PLoS medicine 20071101

• Suzuki-Miyaura and Stille reactions as key steps in the synthesis of diversely functionalized Amaryllidaceae alkaloid analogs bearing a 5,6,7,8-tetrahydrobenzo[c,e]azocine skeleton.

  Combinatorial chemistry & high throughput screening 20071101

• Weight-loss associated with anti-dementia drugs in a patient with Parkinson's disease.

  Movement disorders : official journal of the Movement Disorder Society 20071015

• Baseline predictors of rates of hippocampal atrophy in mild cognitive impairment.

  Neurology 20071009

• Novel class of quinone-bearing polyamines as multi-target-directed ligands to combat Alzheimer's disease.

  Journal of medicinal chemistry 20071004

• Impairments in trace EB conditioning by knife-cut lesions to the fornix in rabbits: reversal by galantamine.

  Neurobiology of learning and memory 20071001

• Treatment of dementia in community-dwelling and institutionalized medicare beneficiaries.

  Journal of the American Geriatrics Society 20071001

• Evaluation of centrally acting cholinesterase inhibitor exposures in adults.

  The Annals of pharmacotherapy 20071001

• Cholinesterase inhibitors: tremor and exacerbation of Parkinson's disease.

  Prescrire international 20071001

• Pharmacotherapy of Alzheimer disease.

  Canadian journal of psychiatry. Revue canadienne de psychiatrie 20071001

• [Cardiovascular effects of cholinesterase inhibitors in Alzheimer's disease].

  Revue neurologique 20071001

• Diagnosis and management of vascular cognitive impairment.

  Current atherosclerosis reports 20071001

• [The localization of galanthamine in vegetative organ of Lycoris aurea Herb].

  Fen zi xi bao sheng wu xue bao = Journal of molecular cell biology 20071001

• Progress update: Pharmacological treatment of Alzheimer's disease.

  Neuropsychiatric disease and treatment 20071001

• Management of dementia with a cerebrovascular component.

  Alzheimer's & dementia : the journal of the Alzheimer's Association 20071001

• [Are anti-dementia drugs worthwhile?].

  MMW Fortschritte der Medizin 20070913

• Cholinesterase inhibitors in dementia with Lewy bodies: a comparative analysis.

  International journal of geriatric psychiatry 20070901

• Statins prevent cholinesterase inhibitor blockade of sympathetic alpha7-nAChR-mediated currents in rat superior cervical ganglion neurons.

  American journal of physiology. Heart and circulatory physiology 20070901

• Synergistic effect of combined treatment with risperidone and galantamine on phencyclidine-induced impairment of latent visuospatial learning and memory: Role of nAChR activation-dependent increase of dopamine D1 receptor-mediated neurotransmission.

  Neuropharmacology 20070901

• Motor-skill learning in Alzheimer's disease: a review with an eye to the clinical practice.

  Neuropsychology review 20070901

• Efficacy and adverse effects of cholinesterase inhibitors and memantine in vascular dementia: a meta-analysis of randomised controlled trials.

  The Lancet. Neurology 20070901

• VRX-03011, a novel 5-HT4 agonist, enhances memory and hippocampal acetylcholine efflux.

  Neuropharmacology 20070901

• Anti-dementia drugs and hippocampal-dependent memory in rodents.

  Behavioural pharmacology 20070901

• Benzylphenethylamine alkaloids from Hosta plantaginea with inhibitory activity against tobacco mosaic virus and acetylcholinesterase.

  Journal of natural products 20070901

• Pharmacogenetic aspects of therapy with cholinesterase inhibitors: the role of CYP2D6 in Alzheimer's disease pharmacogenetics.

  Current Alzheimer research 20070901

• NICE judgement leaves behind a nasty taste.

  Nursing older people 20070901

• [Cholinergic hypothesis in psychosis following traumatic brain injury and cholinergic hypothesis in schizophrenia: a link?].

  L'Encephale 20070901

• Vascular dementia: pharmacological treatment approaches and perspectives.

  Clinical interventions in aging 20070901

• The enantioselective synthesis of (-)-lycoramine with the Birch-Cope sequence.

  The Journal of organic chemistry 20070831

• Effect of galantamine on verbal repetition in AD: a secondary analysis of the VISTA trial.

  Neurology 20070821

• Galantamine postischemia provides neuroprotection and memory recovery against transient global cerebral ischemia in gerbils.

  The Journal of pharmacology and experimental therapeutics 20070801

• Galantamine treatment of vascular dementia: a randomized trial.

  Neurology 20070731

• Leishmanicidal and cholinesterase inhibiting activities of phenolic compounds from Allanblackia monticola and Symphonia globulifera.

  Molecules (Basel, Switzerland) 20070720

• Regional brain activity after prolonged cholinergic enhancement in early Alzheimer's disease.

  Magnetic resonance imaging 20070701

• Competitive antagonism between the nicotinic allosteric potentiating ligand galantamine and kynurenic acid at alpha7* nicotinic receptors.

  The Journal of pharmacology and experimental therapeutics 20070701

• Magnetic resonance imaging predictors of cognition in mild cognitive impairment.

  Archives of neurology 20070701

• Beyond in vitro data: a review of in vivo evidence regarding the allosteric potentiating effect of galantamine on nicotinic acetylcholine receptors in Alzheimer's neuropathology.

  Journal of Alzheimer's disease : JAD 20070701

• Molecular pathology and pharmacogenomics in Alzheimer's disease: polygenic-related effects of multifactorial treatments on cognition, anxiety and depression.

  Methods and findings in experimental and clinical pharmacology 20070701

• High-performance liquid chromatographic method with UV photodiode-array, fluorescence and mass spectrometric detection for simultaneous determination of galantamine and its phase I metabolites in biological samples.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20070615

• Galanthamine and non-competitive inhibitor binding to ACh-binding protein: evidence for a binding site on non-alpha-subunit interfaces of heteromeric neuronal nicotinic receptors.

  Journal of molecular biology 20070615

• Activation of dopamine D1 receptors enhances cholinergic transmission and social cognition: a parallel dialysis and behavioural study in rats.

  The international journal of neuropsychopharmacology 20070601

• Preclinical investigation of the functional effects of memantine and memantine combined with galantamine or donepezil.

  Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 20070601

• The allosteric potentiation of nicotinic acetylcholine receptors by galantamine ameliorates the cognitive dysfunction in beta amyloid25-35 i.c.v.-injected mice: involvement of dopaminergic systems.

  Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 20070601

• The acetylcholinesterase inhibitor galantamine inhibits d-amphetamine-induced psychotic-like behavior in Cebus monkeys.

  The Journal of pharmacology and experimental therapeutics 20070601

• Potential ethnic modifiers in the assessment and treatment of Alzheimer's disease: challenges for the future.

  International psychogeriatrics 20070601

• Memory enhancing drugs and Alzheimer's disease: enhancing the self or preventing the loss of it?

  Medicine, health care, and philosophy 20070601

• EXACT: rivastigmine improves the high prevalence of attention deficits and mood and behaviour symptoms in Alzheimer's disease.

  International journal of clinical practice 20070601

• [Cholinesterase inhibitors and Alzheimer's disease: meta-analysis of the verification of effectiveness, origin and bias of results in published studies].

  Deutsche medizinische Wochenschrift (1946) 20070601

• [Galanthamine versus donepezil in the treatment of Alzheimer's disease].

  Revista de neurologia 20070601

• [Rivastigmine solution prescribing habits in patients with Alzheimer-type dementia in Spain (RIVASOL study)].

  Revista de neurologia 20070601

• Atypical antipsychotics for the treatment of dementia-related behaviors: an update.

  Medicine and health, Rhode Island 20070601

• Synthesis of 6beta-D-glucosyl and 6-nitroxy (-)-galanthamine derivatives as acetylcholinesterase inhibitors.

  Die Pharmazie 20070601

• A rabbit model of Alzheimer's disease: valid at neuropathological, cognitive, and therapeutic levels.

  Journal of Alzheimer's disease : JAD 20070601

• Treating senile dementia with traditional Chinese medicine.

  Clinical interventions in aging 20070601

• Advances in the discovery of novel positive allosteric modulators of the alpha7 nicotinic acetylcholine receptor.

  Recent patents on CNS drug discovery 20070601

• Donepezil in Alzheimer's disease: From conventional trials to pharmacogenetics.

  Neuropsychiatric disease and treatment 20070601

• Mechanisms of over-activated innate immune system regulation in autoimmune and neurodegenerative disorders.

  Neuropsychiatric disease and treatment 20070601

• A case of disseminated polycystic dilated perivascular spaces presenting with dementia and parkinsonism.

  Journal of clinical neurology (Seoul, Korea) 20070601

• [Acetylcholinesterase inhibitors for dementia--an update].

  MMW Fortschritte der Medizin 20070521

• Cholinesterase inhibitors reduce cortical Abeta in dementia with Lewy bodies.

  Neurology 20070515

• Stereocontrolled synthesis of (-)-galanthamine.

  Organic letters 20070510

• Effective pharmacologic management of Alzheimer's disease.

  The American journal of medicine 20070501

• In vitro formulation optimization of intranasal galantamine leading to enhanced bioavailability and reduced emetic response in vivo.

  International journal of pharmaceutics 20070420

• Methyl 2-(2-(4-formylphenoxy)acetamido)-2-substituted acetate derivatives: a new class of acetylcholinesterase inhibitors.

  Bioorganic & medicinal chemistry letters 20070415

• Post-ischemic continuous administration of galantamine attenuates cognitive deficits and hippocampal neurons loss after transient global ischemia in gerbils.

  Neuroscience letters 20070406

• Effect of galantamine on verbal repetition in AD: a secondary analysis of the VISTA trial.

  Neurology 20070403

• Efficacy of cognitive rehabilitation in patients with mild cognitive impairment treated with cholinesterase inhibitors.

  International journal of geriatric psychiatry 20070401

• Acetylcholine and cognition in schizophrenia: effects of galantamine.

  Current psychiatry reports 20070401

• The influence of galantamine on reaction time, attention processes, and performance variability in elderly Alzheimer patients.

  Journal of clinical psychopharmacology 20070401

• Rivastigmine in the treatment of patients with Alzheimer's disease.

  Neuropsychiatric disease and treatment 20070401

• Memantine: efficacy and safety in mild-to-severe Alzheimer's disease.

  Neuropsychiatric disease and treatment 20070401

• Refractory psychosis and prominent cognitive deficits in a patient with mega-cisterna magna.

  Progress in neuro-psychopharmacology & biological psychiatry 20070330

• Comparative analysis of mortality in patients with Alzheimer's disease treated with donepezil and galantamine.

  Age and ageing 20070301

• A 12-week, double-blind, placebo-controlled trial of galantamine adjunctive treatment to conventional antipsychotics for the cognitive impairments in chronic schizophrenia.

  International clinical psychopharmacology 20070301

• A 2-year open-label study of galantamine therapy in Chinese Alzheimer's disease patients in Hong Kong.

  International journal of clinical practice 20070301

• Synergistic effect of galantamine with risperidone on impairment of social interaction in phencyclidine-treated mice as a schizophrenic animal model.

  Neuropharmacology 20070301

• Treatment strategies for the behavioral symptoms of Alzheimer's disease: focus on early pharmacologic intervention.

  Pharmacotherapy 20070301

• Treatment of tardive dyskinesia with galantamine: a randomized controlled crossover trial.

  The Journal of clinical psychiatry 20070301

• Pharmacokinetics and bioequivalence studies of galantamine hydrobromide dispersible tablet in healthy male Chinese volunteers.

  Drug development and industrial pharmacy 20070301

• Frontotemporal dementia: recommendations for therapeutic studies, designs, and approaches.

  The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques 20070301

• Rivastigmine in the treatment of Alzheimer's disease: an update.

  Clinical interventions in aging 20070301

• Galantamine and donepezil attenuate pharmacologically induced deficits in prepulse inhibition in rats.

  Neuropharmacology 20070201

• Anti-Alzheimer drugs: life-threatening adverse effects.

  Prescrire international 20070201

• Quantitative determination of galantamine in human plasma by sensitive liquid chromatography-tandem mass spectrometry using loratadine as an internal standard.

  Journal of chromatographic science 20070201

• Impaired cognition and attention in adults: pharmacological management strategies.

  Neuropsychiatric disease and treatment 20070201

• Nicotinic component of galantamine in the regulation of amyloid precursor protein processing.

  Chemico-biological interactions 20070130

• Changes of cholinesterase activities in the plasma and some tissues following administration of L-carnitine and galanthamine to rats.

  Neuroscience letters 20070116

• Preparation of secolycorines against acetylcholinesterase.

  Bioorganic & medicinal chemistry 20070115

• Development of in situ ion selective sensors for dissolution.

  Analytica chimica acta 20070102

• Galantamine enhances dopaminergic neurotransmission in vivo via allosteric potentiation of nicotinic acetylcholine receptors.

  Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 20070101

• Kynurenic acid leads, dopamine follows: a new case of volume transmission in the brain?

  Journal of neural transmission (Vienna, Austria : 1996) 20070101

• Effect of acetylcholinesterase inhibitors on the binding of nicotinic alpha4beta2 receptor PET radiotracer, (18)F-nifene: A measure of acetylcholine competition.

  Synapse (New York, N.Y.) 20070101

• Treatment of vascular dementia and vascular cognitive impairment.

  The neurologist 20070101

• Effects of statins on cognitive function in patients with Alzheimer's disease in galantamine clinical trials.

  Drugs & aging 20070101

• Effect of a M1 allosteric modulator on scopolamine-induced amnesia.

  Medicinal chemistry (Shariqah (United Arab Emirates)) 20070101

• Galantamine and QTc prolongation.

  The Journal of clinical psychiatry 20070101

• Posttraumatic stress disorder-like symptoms after treatment with acetylcholinesterase inhibitors.

  The Journal of neuropsychiatry and clinical neurosciences 20070101

• Functional outcomes of drug treatment in Alzheimer's disease: A systematic review and meta-analysis.

  Drugs & aging 20070101

• Evaluation of the slopes of cognitive impairment and disability in Alzheimer's disease (AD) patients treated with acetylcholinesterase inhibitors (AChEl).

  Archives of gerontology and geriatrics 20070101

• Anticholinergic drug-induced delirium in an elderly Alzheimer's dementia patient.

  Archives of gerontology and geriatrics 20070101

• Results of galantamine treatment in acute traumatic brain injury.

  Psychosomatics 20070101

• Cholinesterase inhibitors in mild cognitive impairment: a meta-analysis of randomized controlled trials.

  Neurologia i neurochirurgia polska 20070101

• Brain activation in elderly people with and without dementia: Influences of gender and medication.

  The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry 20070101

• Naturalistic treatment of Alzheimer's disease with galantamine: 12-month follow-up from the NATURE study.

  CNS drugs 20070101

• Efficacy and safety of galantamine in patients with dementia with Lewy bodies: a 24-week open-label study.

  Dementia and geriatric cognitive disorders 20070101

• Galantamine for Alzheimer's disease and mild cognitive impairment.

  Neuroepidemiology 20070101

• Risk and predictability of drug interactions in the elderly.

  International review of neurobiology 20070101

• Advancing translational research with the Semantic Web.

  BMC bioinformatics 20070101

• Galantamine effects on memory, spatial cue utilization, and neurotrophic factors in aged female rats.

  Cell transplantation 20070101

• Structural and functional definition of the specificity of a novel caspase-3 inhibitor, Ac-DNLD-CHO.

  BMC pharmacology 20070101

• [EEG and clinical psychophysiological study of functional changes in the chronic ischemic brain with increased acetylcholinergic activity].

  Fiziologiia cheloveka 20070101

• Chronic administration of R-flurbiprofen attenuates learning impairments in transgenic amyloid precursor protein mice.

  BMC neuroscience 20070101

• The clinical meaningfulness of ADAS-Cog changes in Alzheimer's disease patients treated with donepezil in an open-label trial.

  BMC neurology 20070101

• Add-on therapy with acetylcholinesterase inhibitors for memory dysfunction in schizophrenia: a systematic quantitative review, part 2.

  Clinical neuropharmacology 20070101

• Modelling disease progression in Alzheimer's disease: a review of modelling methods used for cost-effectiveness analysis.

  PharmacoEconomics 20070101

• [Alzheimer drugs for mild cognitive impairment].

  Neuropsychiatrie : Klinik, Diagnostik, Therapie und Rehabilitation : Organ der Gesellschaft Osterreichischer Nervenarzte und Psychiater 20070101

• [Criminal clozapine intoxications].

  Anesteziologiia i reanimatologiia 20070101

• Is long-term treatment of Alzheimer's disease with cholinesterase inhibitor therapy justified?

  Drugs & aging 20070101

• Drug interactions with cholinesterase inhibitors: an analysis of the French pharmacovigilance database and a comparison of two national drug formularies (Vidal, British National Formulary).

  Drug safety 20070101

• Recent developments in cholinesterases inhibitors for Alzheimer's disease treatment.

  Current medicinal chemistry 20070101

• Alpha-lipoic acid as a new treatment option for Alzheimer's disease--a 48 months follow-up analysis.

  Journal of neural transmission. Supplementum 20070101

• Brain type carnosinase in dementia: a pilot study.

  BMC neurology 20070101

• What are the benefits of cognitive enhancers for Alzheimer's Disease: use of Population Impact Measures.

  BMC geriatrics 20070101

• NICE cost-effectiveness appraisal of cholinesterase inhibitors: was the right question posed? Were the best tools used?

  PharmacoEconomics 20070101

• Alkaloid variability in Leucojum aestivum from wild populations.

  Zeitschrift fur Naturforschung. C, Journal of biosciences 20070101

• In vitro anticholinesterase activity of various alkaloids.

  Zeitschrift fur Naturforschung. C, Journal of biosciences 20070101

• Short term response is predictive of long term response to acetylcholinesterase inhibitors in Alzheimer's disease: a starting point to explore Bayesian approximation in clinical practice.

  Bioinformation 20070101

• [Efficacy and safety of galantamine (reminyl) in the treatment of dementia in patients with Parkinson's disease (open-label controlled trial)].

  Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova 20070101

• Cholinesterase inhibitor blockade and its prevention by statins of sympathetic alpha7-nAChR-mediated cerebral nitrergic neurogenic vasodilation.

  Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism 20061201

• Potential medicinal plants for CNS disorders: an overview.

  Phytotherapy research : PTR 20061201

• Pharmacological treatment of primary negative symptoms in schizophrenia: a systematic review.

  Schizophrenia research 20061201

• In vitro galantamine-memantine co-application: mechanism of beneficial action.

  Neuropharmacology 20061201

• The anti-amnesic and neuroprotective effects of donepezil against amyloid beta25-35 peptide-induced toxicity in mice involve an interaction with the sigma1 receptor.

  British journal of pharmacology 20061201

• Biomimetic synthesis of (+/-)-galanthamine and asymmetric synthesis of (-)-galanthamine using remote asymmetric induction.

  Chemical & pharmaceutical bulletin 20061201

• Effect of galantamine on acetylcholinesterase and butyrylcholinesterase activities in the presence of L-carnitine in rat selected brain and peripheral tissues.

  Neuro endocrinology letters 20061201

• Evidence-Based Research in Complementary and Alternative Medicine III: Treatment of Patients with Alzheimer's Disease.

  Evidence-based complementary and alternative medicine : eCAM 20061201

• Galantamine reduces smoking in alcohol-dependent patients: a randomized, placebo-controlled trial.

  International journal of clinical pharmacology and therapeutics 20061201

• 6-Hydroxy- and 6-methoxy-beta-carbolines as acetyl- and butyrylcholinesterase inhibitors.

  Bioorganic & medicinal chemistry letters 20061115

• Micellar electrokinetic chromatography-electrospray ionization mass spectrometry for the identification of drug impurities.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20061107

• Neuroprotective effects of galanthamine and tacrine against glutamate neurotoxicity.

  European journal of pharmacology 20061107

• Clinical practice with anti-dementia drugs: a consensus statement from British Association for Psychopharmacology.

  Journal of psychopharmacology (Oxford, England) 20061101

• Cognitive dysfunctions in schizophrenia: potential benefits of cholinesterase inhibitor adjunctive therapy.

  Journal of psychiatry & neuroscience : JPN 20061101

• Blockade of Ca2+ -activated K+ channels by galantamine can also contribute to the potentiation of catecholamine secretion from chromaffin cells.

  European journal of pharmacology 20061024

• Augmentation of near infrared diffuse reflectance and transmittance spectral data for the development of robust PLSBC models for classifying double blind clinical trial tablets.

  Journal of pharmaceutical and biomedical analysis 20061011

• [Medical treatment of Alzheimer's disease].

  Ugeskrift for laeger 20061002

• [Retrospective comparative analysis of antidementia medication persistence patterns in Spanish Alzheimer's disease patients treated with donepezil, rivastigmine, galantamine and memantine].

  Revista de neurologia 20061001

• Use of antidementia agents in vascular dementia: beyond Alzheimer disease.

  Mayo Clinic proceedings 20061001

• A prospective, open-label trial of galantamine in autistic disorder.

  Journal of child and adolescent psychopharmacology 20061001

• Galantamine improves cognition in schizophrenic patients stabilized on risperidone.

  Biological psychiatry 20060915

• Analysis of Amaryllidaceae alkaloids from Narcissus by GC-MS and capillary electrophoresis.

  Journal of pharmaceutical and biomedical analysis 20060911

• Homobivalent quinazolinimines as novel nanomolar inhibitors of cholinesterases with dirigible selectivity toward butyrylcholinesterase.

  Journal of medicinal chemistry 20060907

• Study of PMS777, a new type of acetylcholinesterase inhibitor, in human HepG2 cells. Comparison with tacrine and galanthamine on oxidative stress and mitochondrial impairment.

  Toxicology in vitro : an international journal published in association with BIBRA 20060901

• Identification and pharmacological profile of a new class of selective nicotinic acetylcholine receptor potentiators.

  The Journal of pharmacology and experimental therapeutics 20060901

• Acetylcholinesterase inhibitors used in treatment of Alzheimer's disease prevent glutamate neurotoxicity via nicotinic acetylcholine receptors and phosphatidylinositol 3-kinase cascade.

  Neuropharmacology 20060901

• [Risperidone and cerebrovascular adverse effects in elderly patients with dementia].

  Revista clinica espanola 20060901

• Harmless herbs? Think again: merits of a complete medication history.

  Journal of the American Medical Directors Association 20060901

• Beneficial effects of galantamine on performance in the object recognition task in Swiss mice: deficits induced by scopolamine and by prolonging the retention interval.

  Pharmacology, biochemistry, and behavior 20060901

• Taspine: bioactivity-guided isolation and molecular ligand-target insight of a potent acetylcholinesterase inhibitor from Magnolia x soulangiana.

  Journal of natural products 20060901

• Adjuvant galantamine for cognitive dysfunction in a patient with bipolar disorder.

  Journal of psychiatric practice 20060901

• Sex influences on cholinesterase inhibitor treatment in elderly individuals with Alzheimer's disease.

  The American journal of geriatric pharmacotherapy 20060901

• [Plant metabolites as nootropics and cognitives].

  Ceska a Slovenska farmacie : casopis Ceske farmaceuticke spolecnosti a Slovenske farmaceuticke spolecnosti 20060901

• Vascular dementia: prevention and treatment.

  Clinical interventions in aging 20060901

• Effective countermeasure against poisoning by organophosphorus insecticides and nerve agents.

  Proceedings of the National Academy of Sciences of the United States of America 20060829

• [Advances in Alzheimer's disease treatment].

  La Revue de medecine interne 20060801

• [Cholinesterase inhibitor therapy in long term care settings].

  La Revue de medecine interne 20060801

• [Mechanisms of neuroprotective effects of therapeutic acetylcholinesterase inhibitors used in treatment of Alzheimer's disease].

  Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan 20060801

• Alzheimer's disease.

  Lancet (London, England) 20060729

• [Mortality-associated factors in patients with Alzheimer's disease treated with galantamine].

  Medicina clinica 20060708

• Galantamine added to antipsychotic treatment in chronic schizophrenia: cognitive improvement?

  Schizophrenia research 20060701

• Comparative analysis of mortality in patients with Alzheimer's disease treated with donepezil or galantamine.

  Age and ageing 20060701

• Cognitive effects of adjunctive 24-weeks Rivastigmine treatment to antipsychotics in schizophrenia: a randomized, placebo-controlled, double-blind investigation.

  Schizophrenia research 20060701

• Pharmacology of acetylcholinesterase inhibitors and N-methyl-D-aspartate receptors for combination therapy in the treatment of Alzheimer's disease.

  Journal of clinical pharmacology 20060701

• Rationale for combination therapy with galantamine and memantine in Alzheimer's disease.

  Journal of clinical pharmacology 20060701

• Position statement of the American Association for Geriatric Psychiatry regarding principles of care for patients with dementia resulting from Alzheimer disease.

  The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry 20060701

• Choline pivaloyl ester strengthened the benefit effects of Tacrine and Galantamine on electroencephalographic and cognitive performances in nucleus basalis magnocellularis-lesioned and aged rats.

  Pharmacology, biochemistry, and behavior 20060701

• Effects of galantamine and donepezil on active and passive avoidance tests in rats with induced hypoxia.

  Journal of pharmacological sciences 20060701

• Dementia with lewy bodies: therapeutic opportunities and pitfalls.

  The Consultant pharmacist : the journal of the American Society of Consultant Pharmacists 20060701

• Antiamnesic and neuroprotective effects of donepezil against learning impairments induced in mice by exposure to carbon monoxide gas.

  The Journal of pharmacology and experimental therapeutics 20060601

• Therapeutic utility of a novel tight junction modulating peptide for enhancing intranasal drug delivery.

  Journal of pharmaceutical sciences 20060601

• Vobasinyl-iboga bisindole alkaloids, potent acetylcholinesterase inhibitors from Tabernaemontana divaricata root.

  The Journal of pharmacy and pharmacology 20060601

• Alzheimer's disease: beware of interactions with cholinesterase inhibitors.

  Prescrire international 20060601

• Once-daily formulation of galantamine.

  Journal of the American Medical Directors Association 20060601

• [Pharmacotherapy of a patient with Alzheimer's disease: interactions with the antidementive galantamine].

  Medizinische Monatsschrift fur Pharmazeuten 20060601

• Patterns of cholinesterase-inhibitor use in the nursing home setting: a retrospective analysis.

  The American journal of geriatric pharmacotherapy 20060601

• Treatment of Alzheimer's disease across the spectrum of severity.

  Clinical interventions in aging 20060601

• Economic considerations in the management of Alzheimer's disease.

  Clinical interventions in aging 20060601

• Memantine combined with an acetyl cholinesterase inhibitor - hope for the future?

  Neuropsychiatric disease and treatment 20060601

• [Anti-dementia drugs for dementia syndromes--just unkept promises?].

  MMW Fortschritte der Medizin 20060515

• Efficacy study of galantamine in possible Alzheimer's disease with or without cerebrovascular disease and vascular dementia in Thai patients: a slow-titration regimen.

  International journal of clinical practice 20060501

• Bioactive diterpenes from the fruits of Detarium microcarpum.

  Journal of natural products 20060501

• Quantification of metaxalone in human plasma by liquid chromatography coupled to tandem mass spectrometry.

  Journal of analytical toxicology 20060501

• [Complete atrioventricular block during galantamine therapy].

  Nederlands tijdschrift voor geneeskunde 20060429

• Total synthesis of (+/-)-galanthamine.

  Organic letters 20060427

• Alzheimer's disease drugs promote neurogenesis.

  Brain research 20060426

• High-performance liquid chromatography-mass spectrometry-based acetylcholinesterase assay for the screening of inhibitors in natural extracts.

  Journal of chromatography. A 20060421

• Isoquinoline derivatives as potential acetylcholinesterase inhibitors.

  Bioorganic & medicinal chemistry letters 20060415

• An innovative approach to involve patients in measuring treatment effects in drug trials.

  CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne 20060411

• Attainment of treatment goals by people with Alzheimer's disease receiving galantamine: a randomized controlled trial.

  CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne 20060411

• Inhibition of human acetyl- and butyrylcholinesterase by novel carbamates of (-)- and (+)-tetrahydrofurobenzofuran and methanobenzodioxepine.

  Journal of medicinal chemistry 20060406

• Clinical trials in mild cognitive impairment: lessons for the future.

  Journal of neurology, neurosurgery, and psychiatry 20060401

• Effect of subchronic treatment of memantine, galantamine, and nicotine in the brain of Tg2576 (APPswe) transgenic mice.

  The Journal of pharmacology and experimental therapeutics 20060401

• Accurate product ion mass spectra of galanthamine derivatives.

  Journal of mass spectrometry : JMS 20060401

• Galantamine treatment of cognitive impairment in bipolar disorder: four cases.

  Bipolar disorders 20060401

• Cholinesterase inhibitors: drugs looking for a disease?

  PLoS medicine 20060401

• [Anticholinesterases in the treatment of Alzheimer's disease].

  Revista de neurologia 20060401

• A double-blind comparison of galantamine hydrogen bromide and placebo in adults with attention-deficit/hyperactivity disorder: a pilot study.

  Journal of clinical psychopharmacology 20060401

• Antiamnesic effect of combined treatment with galantamine and estradiol in middle-aged ovariectomized female rats.

  Bulletin of experimental biology and medicine 20060401

• Do cholinergic therapies have disease-modifying effects in Alzheimer's disease?

  Alzheimer's & dementia : the journal of the Alzheimer's Association 20060401

• Novel tricyclic quinazolinimines and related tetracyclic nitrogen bridgehead compounds as cholinesterase inhibitors with selectivity towards butyrylcholinesterase.

  Bioorganic & medicinal chemistry 20060315

• [Complete atrioventricular block during galantamine therapy].

  Nederlands tijdschrift voor geneeskunde 20060311

• Beneficial effect of cholinesterase inhibitor medications on recognition memory performance in mild to moderate Alzheimer's disease: preliminary findings.

  Journal of geriatric psychiatry and neurology 20060301

• Galantamine may improve attention and speech in schizophrenia.

  Human psychopharmacology 20060301

• Time window in cholinomimetic ability to rescue long-term potentiation in neurodegenerating anti-nerve growth factor mice.

  Journal of Alzheimer's disease : JAD 20060301

• Post hoc comparison of daily rates of nausea and vomiting with once- and twice-daily galantamine from a double-blind, placebo-controlled, parallel-group, 6-month study.

  Clinical therapeutics 20060301

• Small vessel disease and subcortical vascular dementia.

  Journal of clinical neurology (Seoul, Korea) 20060301

• Comparison of galantamine and donepezil for effects on nerve growth factor, cholinergic markers, and memory performance in aged rats.

  The Journal of pharmacology and experimental therapeutics 20060201

• Isolation and cholinesterase-inhibition studies of sterols from Haloxylon recurvum.

  Bioorganic & medicinal chemistry letters 20060201

• Acetylcholine nicotinic receptors: finding the putative binding site of allosteric modulators using the 'blind docking' approach.

  Journal of molecular modeling 20060201

• Galantamine for Alzheimer's disease and mild cognitive impairment.

  The Cochrane database of systematic reviews 20060125

• Galantamine for vascular cognitive impairment.

  The Cochrane database of systematic reviews 20060125

• Cholinesterase inhibitors for Alzheimer's disease.

  The Cochrane database of systematic reviews 20060125

• Cognitive evaluation of disease-modifying efficacy of galantamine and memantine in the APP23 model.

  European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology 20060101

• Galantamine increases excitability of CA1 hippocampal pyramidal neurons.

  Neuroscience 20060101

• Cholinergic challenge in Alzheimer patients and mild cognitive impairment differentially affects hippocampal activation--a pharmacological fMRI study.

  Brain : a journal of neurology 20060101

• Effect of the apolipoprotein E epsilon4 allele on the efficacy and tolerability of galantamine in the treatment of Alzheimer's disease.

  Dementia and geriatric cognitive disorders 20060101

• Inhibition of hippocampal function in mild cognitive impairment: targeting the cholinergic hypothesis.

  Neurobiology of aging 20060101

• A systematic review of the clinical effectiveness of donepezil, rivastigmine and galantamine on cognition, quality of life and adverse events in Alzheimer's disease.

  International journal of geriatric psychiatry 20060101

• Galantamine: a cholinergic patch in the treatment of alcoholism: a randomized, placebo-controlled trial.

  Psychopharmacology 20060101

• Alarming arbitrariness in EU prescription and reimbursement criteria for anti-dementia drugs.

  International journal of geriatric psychiatry 20060101

• Novel cholinesterase inhibitors as future effective drugs for the treatment of Alzheimer's disease.

  Expert opinion on investigational drugs 20060101

• Case of the month: rivastigmine (Exelon) toxicity with evidence of respiratory depression.

  Emergency medicine journal : EMJ 20060101

• Circadian cholinergic rhythms: implications for cholinesterase inhibitor therapy.

  Dementia and geriatric cognitive disorders 20060101

• Synthesis and pharmacology of galantamine.

  Chemical reviews 20060101

• Preventing protein secretion with chemical glue.

  Nature chemical biology 20060101

• Rivastigmine monotherapy and combination therapy with memantine in patients with moderately severe Alzheimer's disease who failed to benefit from previous cholinesterase inhibitor treatment.

  International journal of clinical practice 20060101

• The clinical and cost-effectiveness of donepezil, rivastigmine, galantamine and memantine for Alzheimer's disease.

  Health technology assessment (Winchester, England) 20060101

• Galantamine-induced QTc prolongation.

  The Journal of clinical psychiatry 20060101

• Pharmacological and molecular enhancement of learning in aging and Alzheimer's disease.

  Journal of physiology, Paris 20060101

• QEEG monitoring of Alzheimer's disease treatment: a preliminary report of three case studies.

  Clinical EEG and neuroscience 20060101

• [Use of reminyl (galantamine) in the treatment of dementia].

  Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova 20060101

• Neuroprotection in vascular dementia.

  Cerebrovascular diseases (Basel, Switzerland) 20060101

• Current and emerging pharmacological treatment options for dementia.

  Behavioural neurology 20060101

• [Are the prescriptions of anticholinesterasic drugs adapted to the associated diseases and/or drugs in the Alzheimer's dementia?].

  Therapie 20060101

• [Observational study on safety, tolerability and effectiveness of galantamine in patients with mild to moderately severe Alzheimer's disease].

  Neurologia (Barcelona, Spain) 20060101

• Sensory gating deficits, pattern completion, and disturbed fronto-limbic balance, a model for description of hallucinations and delusions in schizophrenia.

  Medical hypotheses 20060101

• Galantamine extended release.

  CNS drugs 20060101

• Acetylcholinesterase inhibitors and sleep architecture in patients with Alzheimer's disease.

  Drugs & aging 20060101

• [Optimizing effect of the combined administration of 8-OH-DPAT and galantamine on depression--anxiety behavior in old rats with dementia of Alzheimer's type].

  Eksperimental'naia i klinicheskaia farmakologiia 20060101

• Phenomenology and management of cognitive and behavioral disorders in Parkinson's disease. Rise and logic of dementia in Parkinson's disease.

  Annals of general psychiatry 20060101

• A systematic review of assessment and treatment of moderate to severe Alzheimer's disease.

  Primary care companion to the Journal of clinical psychiatry 20060101

• Towards a unifying hypothesis of Alzheimer's disease: cholinergic system linked to plaques, tangles and neuroinflammation.

  Current medicinal chemistry 20060101

• Galantamine was effective in mild-to-moderate Alzheimer disease.

  ACP journal club 20060101

• [Pharmacotherapy for Alzheimer's disease].

  Tijdschrift voor psychiatrie 20060101

• Kinetics of 13 new cholinesterase inhibitors.

  Zeitschrift fur Naturforschung. C, Journal of biosciences 20060101

• Cholinesterase inhibitors in the clinical management of Alzheimer's disease: importance of early and persistent treatment.

  The Journal of international medical research 20060101

• A naturalistic study of galantamine for Alzheimer's disease.

  CNS drugs 20060101

• Mitochondrial oxidative damage in aging and Alzheimer's disease: implications for mitochondrially targeted antioxidant therapeutics.

  Journal of biomedicine & biotechnology 20060101

• Roles of cholesterol and lipids in the etiopathogenesis of Alzheimer's disease.

  Journal of biomedicine & biotechnology 20060101

• Determination of therapeutics with growth-hormone secretagogue activity in human urine for doping control purposes.

  Rapid communications in mass spectrometry : RCM 20060101

• Initiation of acetylcholinesterase inhibitors and complications of chronic airways disorders in elderly patients.

  Drug safety 20060101

• Realistic expectations for treatment success in Alzheimer's disease.

  The journal of nutrition, health & aging 20060101

• Galantamine extended release in Alzheimer's disease: profile report.

  Drugs & aging 20060101

• Alzheimer disease and its management: a review.

  American journal of therapeutics 20060101

• Recommendations for best practices in the treatment of Alzheimer's disease in managed care.

  The American journal of geriatric pharmacotherapy 20060101

• The effect of drugs for Alzheimer disease assessed by means of neuroradiological techniques.

  Current medicinal chemistry 20060101

• Neuroprotection by nicotine in hippocampal slices subjected to oxygen-glucose deprivation: involvement of the alpha7 nAChR subtype.

  Journal of molecular neuroscience : MN 20060101

• The N-butylcarbamate derivative of galantamine acts as an allosteric potentiating ligand on alpha7 nicotinic receptors in hippocampal neurons: clinical implications for treatment of Alzheimer's disease.

  Journal of molecular neuroscience : MN 20060101

• Galanthamine, a natural product for the treatment of Alzheimer's disease.

  Recent patents on CNS drug discovery 20060101

• Neurogenesis and Alzheimer's disease.

  Drug target insights 20060101

• Donepezil in Alzheimer's disease: an evidence-based review of its impact on clinical and economic outcomes.

  Core evidence 20060101

• Synthesis of tricyclic 1,3-oxazin-4-ones and kinetic analysis of cholesterol esterase and acetylcholinesterase inhibition.

  Journal of medicinal chemistry 20051229

• Drug discovery from medicinal plants.

  Life sciences 20051222

• Up-regulation of nicotinic acetylcholine receptors by central-type acetylcholinesterase inhibitors in rat cortical neurons.

  European journal of pharmacology 20051219

• Age-related deficits in the retention of memories for cued fear conditioning are reversed by galantamine treatment.

  Behavioural brain research 20051207

• Differential effect of PMS777, a new type of acetylcholinesterase inhibitor, and galanthamine on oxidative injury induced in human neuroblastoma SK-N-SH cells.

  Neuroscience letters 20051202

• Cholinesterase inhibitors ameliorate behavioral deficits induced by MK-801 in mice.

  Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 20051201

• Pharmacological modulation of cholinergic brain activity and its reflection in special EEG frequency ranges from various brain areas in the freely moving rat (Tele-Stereo-EEG).

  European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology 20051201

• Unequal neuroprotection afforded by the acetylcholinesterase inhibitors galantamine, donepezil, and rivastigmine in SH-SY5Y neuroblastoma cells: role of nicotinic receptors.

  The Journal of pharmacology and experimental therapeutics 20051201

• A case with cholinesterase inhibitor responsive asymmetric posterior cortical atrophy.

  Clinical neurology and neurosurgery 20051201

• Nostocarboline: isolation and synthesis of a new cholinesterase inhibitor from Nostoc 78-12A.

  Journal of natural products 20051201

• Galantamine antiacetylcholinesterase activity in rat brain influenced by L-carnitine.

  Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia 20051201

• Dementia.

  Clinical evidence 20051201

• Mild traumatic brain injury: a neuropsychiatric approach to diagnosis, evaluation, and treatment.

  Neuropsychiatric disease and treatment 20051201

• Nicotinic-receptor potentiator drugs, huprine X and galantamine, increase ACh release by blocking AChE activity but not acting on nicotinic receptors.

  Brain research 20051109

• Mild cognitive impairment: to treat or not to treat.

  Current neurology and neuroscience reports 20051101

• Behavioral and neuropsychiatric outcomes in Alzheimer's disease.

  CNS spectrums 20051101

• A case report of paranoid delusion with galantamine use.

  Journal of the American Geriatrics Society 20051101

• Effects of switching from an AChE inhibitor to a dual AChE-BuChE inhibitor in patients with Alzheimer's disease.

  Current medical research and opinion 20051101

• Divergent enantioselective synthesis of (-)-galanthamine and (-)-morphine.

  Journal of the American Chemical Society 20051026

• Reduction of voluntary ethanol consumption in alcohol-preferring Alko alcohol (AA) rats by desoxypeganine and galanthamine.

  European journal of pharmacology 20051017

• Modulation of N-methyl-D-aspartate receptors by donepezil in rat cortical neurons.

  The Journal of pharmacology and experimental therapeutics 20051001

• Adjuvant galantamine to risperidone improves negative and cognitive symptoms in a patient presenting with schizophrenialike psychosis after traumatic brain injury.

  Journal of clinical psychopharmacology 20051001

• Do MCI criteria in drug trials accurately identify subjects with predementia Alzheimer's disease?

  Journal of neurology, neurosurgery, and psychiatry 20051001

• Pharmacogenomics and therapeutic prospects in Alzheimer's disease.

  Expert opinion on pharmacotherapy 20051001

• Pharmacokinetics of extended-release and immediate-release formulations of galantamine at steady state in healthy volunteers.

  Current medical research and opinion 20051001

• New anti-Alzheimer drugs from biodiversity: the role of the natural acetylcholinesterase inhibitors.

  Mini reviews in medicinal chemistry 20051001

• Undertreatment of patients with Alzheimer's disease in an elderly United States population.

  Alzheimer's & dementia : the journal of the Alzheimer's Association 20051001

• [Nightmares in patients with Alzheimer's disease caused by donepezil. Therapeutic effect depends on the time of intake].

  Der Nervenarzt 20050901

• UK government guidance on Alzheimer's drugs postponed.

  Drug discovery today 20050901

• Early onset effects of galantamine treatment on attention in patients with Alzheimer's disease.

  Current medical research and opinion 20050901

• [Traditional dementia concepts in transition--must we change our views?].

  Der Nervenarzt 20050901

• Galantamine-induced behavioral recovery after sublethal excitotoxic lesions to the rat medial septum.

  Behavioural brain research 20050830

• Cholinesterase inhibitors for patients with Alzheimer's disease: systematic review of randomised clinical trials.

  BMJ (Clinical research ed.) 20050806

• Cellular responses to nicotinic receptor activation are decreased after prolonged exposure to galantamine in human neuroblastoma cells.

  British journal of pharmacology 20050801

• Development of a novel high-concentration galantamine formulation suitable for intranasal delivery.

  Journal of pharmaceutical sciences 20050801

• Effect of galantamine on the human alpha7 neuronal nicotinic acetylcholine receptor, the Torpedo nicotinic acetylcholine receptor and spontaneous cholinergic synaptic activity.

  British journal of pharmacology 20050701

• A cohort study of effectiveness of acetylcholinesterase inhibitors in Alzheimer's disease.

  European journal of clinical pharmacology 20050701

• Cognitive performance in patients with Alzheimer's disease receiving cholinesterase inhibitors for up to 5 years.

  International journal of clinical practice 20050701

• [Pharmacological therapy in Alzheimer's disease. Current clinical practice in The Netherlands].

  Tijdschrift voor gerontologie en geriatrie 20050701

• Predicting drug metabolism--an evaluation of the expert system METEOR.

  Chemistry & biodiversity 20050701

• Acute effects of physostigmine and galantamine on the binding of [18F]fluoro-A-85380: a PET study in monkeys.

  Synapse (New York, N.Y.) 20050615

• Indole alkaloids from Tabernaemontana australis (Muell. Arg) Miers that inhibit acetylcholinesterase enzyme.

  Bioorganic & medicinal chemistry 20050602

• Symptomatic effect of donepezil, rivastigmine, galantamine and memantine on cognitive deficits in the APP23 model.

  Psychopharmacology 20050601

• Quantitative and cytotoxic activity determinations on Galanthus nivalis subsp. cilicicus.

  Fitoterapia 20050601

• Reduction of caregiver burden in Alzheimer's disease by treatment with galantamine.

  CNS spectrums 20050601

• Effects of cholinesterase inhibitors appear greater in patients on established antihypertensive therapy.

  International journal of geriatric psychiatry 20050601

• Galantamine treatment of problematic behavior in Alzheimer disease: post-hoc analysis of pooled data from three large trials.

  The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry 20050601

• Prediction of genotoxicity of chemical compounds by statistical learning methods.

  Chemical research in toxicology 20050601

• [Changing the anticholinesterase in Alzheimer's disease].

  Revista de neurologia 20050601

• Galantamine: excess mortality.

  Prescrire international 20050601

• Nicotinic agonists, antagonists, and modulators from natural sources.

  Cellular and molecular neurobiology 20050601

• Stimulation of nicotinic acetylcholine receptors protects motor neurons.

  Biochemical and biophysical research communications 20050520

• Steady-state pharmacokinetics of galantamine are not affected by addition of memantine in healthy subjects.

  Journal of clinical pharmacology 20050501

• Switching from donepezil to galantamine: a double-blind study of two wash-out periods.

  International journal of geriatric psychiatry 20050501

• Metabolic patterns associated with the clinical response to galantamine therapy: a fludeoxyglucose f 18 positron emission tomographic study.

  Archives of neurology 20050501

• A comparison of donepezil and galantamine in the treatment of cognitive symptoms of Alzheimer's disease: a meta-analysis.

  Human psychopharmacology 20050401

• Capillary electrophoresis-mass spectrometry in impurity profiling of pharmaceutical products.

  Electrophoresis 20050401

• [Cost-effectiveness of galantamine in a german context].

  Psychiatrische Praxis 20050401

• Actions of tacrine and galanthamine on histamine-N-methyltransferase.

  Methods and findings in experimental and clinical pharmacology 20050401

• Pharmacokinetic simulation for switching from galantamine immediate-release to extended-release formulation.

  Current medical research and opinion 20050401

• [Determination of galanthamine in bulb of Lycoris radiata by RP-HPLC].

  Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica 20050401

• Memantine blocks alpha7* nicotinic acetylcholine receptors more potently than n-methyl-D-aspartate receptors in rat hippocampal neurons.

  The Journal of pharmacology and experimental therapeutics 20050301

• Cholinesterase inhibitors in the treatment of dementia.

  The Journal of the American Osteopathic Association 20050301

• Pharmacologic treatment options in Alzheimer's disease: optimizing disease management.

  Journal of the American Academy of Nurse Practitioners 20050301

• Mild cognitive impairment in Parkinson's disease: the challenge and the promise.

  Neuropsychiatric disease and treatment 20050301

• Novel anticholinesterases based on the molecular skeletons of furobenzofuran and methanobenzodioxepine.

  Journal of medicinal chemistry 20050224

• Galantamine activates muscle-type nicotinic acetylcholine receptors without binding to the acetylcholine-binding site.

  The Journal of neuroscience : the official journal of the Society for Neuroscience 20050223

• Cholinergic drugs potentiate human nicotinic alpha4beta2 acetylcholine receptors by a competitive mechanism.

  European journal of pharmacology 20050221

• Brain levels and acetylcholinesterase inhibition with galantamine and donepezil in rats, mice, and rabbits.

  Brain research 20050208

• Regulatory authorities review use of galantamine in mild cognitive impairment.

  BMJ (Clinical research ed.) 20050205

• Butyrylcholinesterase inhibitory guaianolides from Amberboa ramosa.

  Archives of pharmacal research 20050201

• [Acetylcholinesterase inhibitor treatment for Alzheimer's disease: the experience in Picardy].

  Revue neurologique 20050201

• Indicators of neuroprotection with galantamine.

  Brain research bulletin 20050130

• Effect of cholinergic medication, before and after focal photothrombotic ischemic cortical injury, on histological and functional outcome in aged and young adult rats.

  Behavioural brain research 20050106

• Central acetylcholinesterase inhibitors in the treatment of chronic traumatic brain injury-clinical experience in 111 patients.

  Progress in neuro-psychopharmacology & biological psychiatry 20050101

• Not all head-to-head trials are created equal: results from an open-label, short-term study seem inconsistent with previous donepezil literature.

  International journal of geriatric psychiatry 20050101

• Look-alike, sound-alike drug errors with Reminyl and Amaryl.

  American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20050101

• Differential efficacy of treatment with acetylcholinesterase inhibitors in patients with mild and moderate Alzheimer's disease over a 6-month period.

  Dementia and geriatric cognitive disorders 20050101

• [Treatment of dementia].

  Nihon Ronen Igakkai zasshi. Japanese journal of geriatrics 20050101

• Integrated treatment approach improves cognitive function in demented and clinically depressed patients.

  American journal of Alzheimer's disease and other dementias 20050101

• Portals to Wonderland: health portals lead to confusing information about the effects of health care.

  BMC medical informatics and decision making 20050101

• Cholinesterase inhibitor affects the amyloid precursor protein isoforms in patients with Alzheimer's disease.

  Dementia and geriatric cognitive disorders 20050101

• Metabolites from Microsphaeropsis olivacea, an endophytic fungus of Pilgerodendron uviferum.

  Zeitschrift fur Naturforschung. C, Journal of biosciences 20050101

• CGC-MS of alkaloids in Leucojum aestivum plants and their in vitro cultures.

  Phytochemical analysis : PCA 20050101

• Natural products and derivatives affecting neurotransmission relevant to Alzheimer's and Parkinson's disease.

  Neuro-Signals 20050101

• The effect of galantamine added to clozapine on cognition of five patients with schizophrenia.

  Clinical neuropharmacology 20050101

• [Pharmacology of Alzheimer's disease: where do we go from here?].

  Therapie 20050101

• Galantamine prolonged-release formulation in the treatment of mild to moderate Alzheimer's disease.

  Dementia and geriatric cognitive disorders 20050101

• Treating patients with moderate to severe Alzheimer's disease: implications of recent pharmacologic studies.

  Primary care companion to the Journal of clinical psychiatry 20050101

• Drug therapy of dementia in elderly patients. A review.

  Nordic journal of psychiatry 20050101

• Effects of galantamine on working memory and global functioning in patients with mild cognitive impairment: a double-blind placebo-controlled study.

  American journal of Alzheimer's disease and other dementias 20050101

• [Reminyl efficacy in dementia with Levi bodies].

  Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova 20050101

• Effects of galantamine versus donepezil on sleep in patients with mild to moderate Alzheimer disease and their caregivers: a double-blind, head-to-head, randomized pilot study.

  Alzheimer disease and associated disorders 20050101

• Modelling the cost effectiveness of cholinesterase inhibitors in the management of mild to moderately severe Alzheimer's disease.

  PharmacoEconomics 20050101

• Emergent complications following donepezil switchover to galantamine in three cases of dementia with Lewy bodies.

  The Journal of neuropsychiatry and clinical neurosciences 20050101

• [Use of acetylcholinesterase inhibitors and memantine in Alzheimer-type dementia].

  Revista espanola de salud publica 20050101

• Guidelines for the treatment of Alzheimer's disease from the Italian Association of Psychogeriatrics.

  Drugs & aging 20050101

• The expert consensus guideline series. Treatment of dementia and its behavioral disturbances. Introduction: methods, commentary, and summary.

  Postgraduate medicine 20050101

• Galantamine modulates nicotinic receptor and blocks Abeta-enhanced glutamate toxicity.

  Biochemical and biophysical research communications 20041217

• Acetylcholinesterase inhibitory activity of scopolin and scopoletin discovered by virtual screening of natural products.

  Journal of medicinal chemistry 20041202

• The complex of a bivalent derivative of galanthamine with torpedo acetylcholinesterase displays drastic deformation of the active-site gorge: implications for structure-based drug design.

  Journal of the American Chemical Society 20041201

• Novel neuronal targets for the acetylcholinesterase inhibitor donepezil.

  Neuropharmacology 20041201

• Challenging the cholinergic system in mild cognitive impairment: a pharmacological fMRI study.

  NeuroImage 20041201

• Adjuvant therapeutic effects of galantamine on apathy in a schizophrenia patient.

  The Journal of clinical psychiatry 20041201

• Improved production of galanthamine and related alkaloids by methyl jasmonate in Narcissus confusus shoot-clumps.

  Planta medica 20041201

• Dementia.

  Clinical evidence 20041201

• Pharmacotherapy of mild cognitive impairment.

  Dialogues in clinical neuroscience 20041201

• Mild cognitive impairment: historical development and summary of research.

  Dialogues in clinical neuroscience 20041201

• Galantamine blocks cloned Kv2.1, but not Kv1.5 potassium channels.

  Brain research. Molecular brain research 20041124

• Treatment of vascular dementia--evidence from clinical trials with cholinesterase inhibitors.

  Journal of the neurological sciences 20041115

• Switching from donepezil or rivastigmine to galantamine in clinical practice.

  Journal of the American Geriatrics Society 20041101

• Mechanisms of action of cognitive enhancers on neuroreceptors.

  Biological & pharmaceutical bulletin 20041101

• Isolation of the acetylcholinesterase inhibitor ungeremine from Nerine bowdenii by preparative HPLC coupled on-line to a flow assay system.

  Biological & pharmaceutical bulletin 20041101

• Long-term efficacy and safety of galantamine in patients with mild-to-moderate Alzheimer's disease: multicenter trial.

  European journal of neurology 20041101

• An open-label, comparative study of rivastigmine, donepezil and galantamine in a real-world setting.

  Current medical research and opinion 20041101

• Effects of galantamine in patients with mild Alzheimer's disease.

  Current medical research and opinion 20041101

• Indole glucoalkaloids from Chimarrhis turbinata and their evaluation as antioxidant agents and acetylcholinesterase inhibitors.

  Journal of natural products 20041101

• Systematic review of cholinergic drugs for neuroleptic-induced tardive dyskinesia: a meta-analysis of randomized controlled trials.

  Progress in neuro-psychopharmacology & biological psychiatry 20041101

• [Natural progression of Alzheimer's disease (AD): a perspective on possible therapies for advanced AD].

  Rinsho shinkeigaku = Clinical neurology 20041101

• Enhancement of purinergic neurotransmission by galantamine and other acetylcholinesterase inhibitors in the rat vas deferens.

  European journal of pharmacology 20041025

• Galantamine for Alzheimer's disease.

  The Cochrane database of systematic reviews 20041018

• Acetylcholinesterase inhibitors: novel activities of old molecules.

  Pharmacological research 20041001

• Different TMS patterns of intracortical inhibition in early onset Alzheimer dementia and frontotemporal dementia.

  Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology 20041001

• Reversible Pisa syndrome (pleurothotonus) due to the cholinesterase inhibitor galantamine: case report.

  Movement disorders : official journal of the Movement Disorder Society 20041001

• Cognitive dysfunction and dementia in Parkinson's disease.

  Journal of neural transmission (Vienna, Austria : 1996) 20041001

• Xanthones from Gentiana campestris as new acetylcholinesterase inhibitors.

  Planta medica 20041001

• A prospective, double-blind, community-controlled comparison of three doses of galantamine in the treatment of mild to moderate Alzheimer's disease in a Korean population.

  Clinical therapeutics 20041001

• In vivo and in vitro study of the influence of the anticholinesterase drug galantamine on motor and evacuative functions of rat gastrointestinal tract.

  European journal of pharmacology 20040913

• Effect of galantamine hydrobromide in chronic fatigue syndrome: a randomized controlled trial.

  JAMA 20040908

• Pharmacotherapy of chronic fatigue syndrome: another gallant attempt.

  JAMA 20040908

• Mechanism of action of galantamine on N-methyl-D-aspartate receptors in rat cortical neurons.

  The Journal of pharmacology and experimental therapeutics 20040901

• Evidence-based pharmacotherapy of Alzheimer's disease.

  The international journal of neuropsychopharmacology 20040901

• Co-administration of memantine has no effect on the in vitro or ex vivo determined acetylcholinesterase inhibition of rivastigmine in the rat brain.

  Neuropharmacology 20040901

• Cholinergic drugs for Alzheimer's disease enhance in vitro dopamine release.

  Molecular pharmacology 20040901

• Regulation of nicotinic acetylcholine receptor channel function by acetylcholinesterase inhibitors in rat hippocampal CA1 interneurons.

  Molecular pharmacology 20040901

• The benefits and risks associated with cholinesterase inhibitor therapy in Alzheimer's disease.

  Expert opinion on drug safety 20040901

• Effect of subchronic galantamine treatment on neuronal nicotinic and muscarinic receptor subtypes in transgenic mice overexpressing human acetylcholinesterase.

  Neuropharmacology 20040901

• Dementia in idiopathic Parkinson's syndrome.

  Journal of neurology 20040901

• Behavioral disturbances in Parkinson's disease.

  Dialogues in clinical neuroscience 20040901

• Galantamine and nicotine have a synergistic effect on inhibition of microglial activation induced by HIV-1 gp120.

  Brain research bulletin 20040830

• Cholinesterase inhibitors modify the activity of intrinsic cardiac neurons.

  Experimental neurology 20040801

• Donepezil is more effective than galantamine for mild to moderate Alzheimer's disease.

  Evidence-based mental health 20040801

• [Drug-cholinesterase-inhibitors persistence patterns in treated patients with dementia of Alzheimer type: retrospective comparative analysis of donepezil, rivastigmine and galantamine].

  Revista de neurologia 20040801

• Gastrointestinal adverse events in a general population sample of nursing home residents taking cholinesterase inhibitors.

  The Consultant pharmacist : the journal of the American Society of Consultant Pharmacists 20040801

• Galantamine and memantine produce different degrees of neuroprotection in rat hippocampal slices subjected to oxygen-glucose deprivation.

  Neuroscience letters 20040722

• A case study in the treatment of dementia with Lewy bodies.

  Acta psychiatrica Scandinavica 20040701

• Galantamine maintains ability to perform activities of daily living in patients with Alzheimer's disease.

  Journal of the American Geriatrics Society 20040701

• What is the rationale for new treatment strategies in Alzheimer's disease?

  CNS spectrums 20040701

• Understanding the latest advances in pharmacologic interventions for Alzheimer's disease.

  CNS spectrums 20040701

• Treatment of vascular dementia-evidence from clinical trials with cholinesterase inhibitors.

  Neurological research 20040701

• [Galantamine, an acetylcholinesterase inhibitor with various actions].

  Medizinische Monatsschrift fur Pharmazeuten 20040701

• Effects of galantamine, a nicotinic allosteric potentiating ligand, on nicotine-induced catecholamine release in hippocampus and nucleus accumbens of rats.

  The Journal of pharmacology and experimental therapeutics 20040601

• Galanthamine from snowdrop--the development of a modern drug against Alzheimer's disease from local Caucasian knowledge.

  Journal of ethnopharmacology 20040601

• Effects of galantamine on behavioural and psychological disturbances and caregiver burden in patients with Alzheimer's disease.

  Current medical research and opinion 20040601

• Cholinergic targets for cognitive enhancement in schizophrenia: focus on cholinesterase inhibitors and muscarinic agonists.

  Psychopharmacology 20040601

• Review of donepezil, rivastigmine, galantamine and memantine for the treatment of dementia in Alzheimer's disease in adults with Down syndrome: implications for the intellectual disability population.

  International journal of geriatric psychiatry 20040601

• Effects of galantamine on attention and memory in Alzheimer's disease measured by computerized neuropsychological tests: results of the Brazilian Multi-Center Galantamine Study (GAL-BRA-01).

  Arquivos de neuro-psiquiatria 20040601

• ApoE genotyping and response to galanthamine in Alzheimer's disease--a real life retrospective study.

  Collegium antropologicum 20040601

• Dementia.

  Clinical evidence 20040601

• [Current antidementive therapy].

  MMW Fortschritte der Medizin 20040524

• Total synthesis of (-)-galanthamine by remote asymmetric induction.

  Angewandte Chemie (International ed. in English) 20040510

• The clinical efficacy and safety of galantamine in the treatment of Alzheimer's disease.

  CNS spectrums 20040501

• Pharmacotherapeutic approaches to the treatment of Alzheimer's disease.

  Clinical therapeutics 20040501

• [Current therapies in dementia].

  Nihon Ronen Igakkai zasshi. Japanese journal of geriatrics 20040501

• Drug therapy for Alzheimer's disease.

  CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne 20040427

• Emerging therapies for vascular dementia and vascular cognitive impairment.

  Stroke 20040401

• Examination of nighttime sleep-related problems during double-blind, placebo-controlled trials of galantamine in patients with Alzheimer's disease.

  Current medical research and opinion 20040401

• Reduction of behavioral disturbances and caregiver distress by galantamine in patients with Alzheimer's disease.

  The American journal of psychiatry 20040301

• Intraspecific variability in the alkaloid metabolism of Galanthus elwesii.

  Phytochemistry 20040301

• Galantamine: use in Alzheimer's disease and related disorders.

  Expert review of neurotherapeutics 20040301

• The use of zebrafish mutants to identify secondary target effects of acetylcholine esterase inhibitors.

  Toxicological sciences : an official journal of the Society of Toxicology 20040201

• The cognitive benefits of galantamine are sustained for at least 36 months: a long-term extension trial.

  Archives of neurology 20040201

• A 6-month open-label study of the effectiveness and tolerability of galantamine in patients with Alzheimer's disease.

  International journal of clinical practice 20040201

• Management of patients with Alzheimer's disease plus cerebrovascular disease: 12-month treatment with galantamine.

  Dementia and geriatric cognitive disorders 20040101

• Cholinesterase inhibitor therapies and neuropsychiatric manifestations of Alzheimer's disease.

  Dementia and geriatric cognitive disorders 20040101

• Potentiation effects of (+/-)huprine X, a new acetylcholinesterase inhibitor, on nicotinic receptors in rat cortical synaptosomes.

  Neuropharmacology 20040101

• Galantamine prevents apoptosis induced by beta-amyloid and thapsigargin: involvement of nicotinic acetylcholine receptors.

  Neuropharmacology 20040101

• Pharmacologic treatment expectations in the management of dementia with Lewy bodies.

  Dementia and geriatric cognitive disorders 20040101

• Efficacy and safety of galantamine in patients with dementia with Lewy bodies: a 12-week interim analysis.

  Dementia and geriatric cognitive disorders 20040101

• A multinational, randomised, 12-week study comparing the effects of donepezil and galantamine in patients with mild to moderate Alzheimer's disease.

  International journal of geriatric psychiatry 20040101

• Cholinesterase inhibitors and vascular dementia: another string to their bow?

  CNS drugs 20040101

• Galantamine facilitates acquisition of hippocampus-dependent trace eyeblink conditioning in aged rabbits.

  Learning & memory (Cold Spring Harbor, N.Y.) 20040101

• Galantamine facilitates acquisition of a trace-conditioned eyeblink response in healthy, young rabbits.

  Learning & memory (Cold Spring Harbor, N.Y.) 20040101

• Acetylcholinesterase inhibition in Alzheimer's Disease.

  Current pharmaceutical design 20040101

• Pharmacokinetics and tissue distribution of galantamine and galantamine-related radioactivity after single intravenous and oral administration in the rat.

  Arzneimittel-Forschung 20040101

• Treatment of Huntington's disease with galantamine.

  International clinical psychopharmacology 20040101

• Cholinesterase inhibitors used in the treatment of Alzheimer's disease: the relationship between pharmacological effects and clinical efficacy.

  Drugs & aging 20040101

• [Drug therapy for aged patients with Alzheimer disease].

  Seishin shinkeigaku zasshi = Psychiatria et neurologia Japonica 20040101

• [The virtual synapse what is its contribution to understanding cholinergic neural transmission?].

  Therapie 20040101

• Effectiveness and safety of cholinesterase inhibitors in elderly subjects with Alzheimer's disease: a 'real world' study.

  Archives of gerontology and geriatrics. Supplement 20040101

• What are the treatment options for patients with severe Alzheimer's disease?

  CNS drugs 20040101

• The use, benefits, and costs of cholinesterase inhibitors for Alzheimer's dementia in long-term care: are the data relevant and available?

  Journal of the American Medical Directors Association 20040101

• Wernicke-Korsakoff syndrome and galantamine.

  Psychosomatics 20040101

• Ginkgo biloba compared with cholinesterase inhibitors in the treatment of dementia: a review based on meta-analyses by the cochrane collaboration.

  Dementia and geriatric cognitive disorders 20040101

• Metaanalysis of randomized trials of the efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer disease.

  The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry 20040101

• Long-term treatment of Alzheimer disease: efficacy and safety of acetylcholinesterase inhibitors.

  Alzheimer disease and associated disorders 20040101

• Noncognitive symptoms and long-term treatment expectations for Alzheimer disease.

  Alzheimer disease and associated disorders 20040101

• The needs of the caregiver in the long-term treatment of Alzheimer disease.

  Alzheimer disease and associated disorders 20040101

• The economic benefits of acetylcholinesterase inhibitors for patients with Alzheimer disease and associated dementias.

  Alzheimer disease and associated disorders 20040101

• Assessing the health and economic impact of galantamine treatment in patients with Alzheimer's disease in the health care systems of different countries.

  Drugs & aging 20040101

• Long-term outcomes of galantamine treatment in patients with Alzheimer disease.

  The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry 20040101

• Alleviation of multiple abnormalities by galantamine treatment in two patients with dementia with Lewy bodies.

  American journal of Alzheimer's disease and other dementias 20040101

• Long-term cholinesterase inhibitor treatment of Alzheimer's disease.

  CNS drugs 20040101

• An overview of the current and novel drugs for Alzheimer's disease with particular reference to anti-cholinesterase compounds.

  Current pharmaceutical design 20040101

• Development of bivalent acetylcholinesterase inhibitors as potential therapeutic drugs for Alzheimer's disease.

  Current pharmaceutical design 20040101

• New classes of AChE inhibitors with additional pharmacological effects of interest for the treatment of Alzheimer's disease.

  Current pharmaceutical design 20040101

• Molecular recognition between 4a S/R-galanthamine diastereoisomers and alpha-cyclodextrin.

  Journal of molecular modeling 20031201

• Antimalarial activity screening of some alkaloids and the plant extracts from Amaryllidaceae.

  Phytotherapy research : PTR 20031201

• Galanthamine distribution in Bulgarian Galanthus spp.

  Die Pharmazie 20031201

• Galanthamine pattern in Narcissus confusus plants.

  Planta medica 20031201

• A case history illustrating how extended release cholinesterase inhibitors could improve management of Alzheimer's disease.

  Journal of Alzheimer's disease : JAD 20031201

• Anticholinesterases in Alzheimer's disease: a modest effect on moderately severe disease.

  Prescrire international 20031201

• Modulation of cholinergic transmission enhances excitability of hippocampal pyramidal neurons and ameliorates learning impairments in aging animals.

  Neurobiology of learning and memory 20031101

• The allosteric potentiation of nicotinic acetylcholine receptors by galantamine is transduced into cellular responses in neurons: Ca2+ signals and neurotransmitter release.

  Molecular pharmacology 20031101

• Long-term safety and cognitive effects of galantamine in the treatment of probable vascular dementia or Alzheimer's disease with cerebrovascular disease.

  European journal of neurology 20031101

• Editorial comment--How to treat vascular dementia?

  Stroke 20031001

• Treatment of dementia with neurotransmission modulation.

  Expert opinion on investigational drugs 20031001

• Cognitive, psychiatric and motor response to galantamine in Parkinson's disease with dementia.

  International journal of geriatric psychiatry 20031001

• The effects of galantamine treatment on caregiver time in Alzheimer's disease.

  International journal of geriatric psychiatry 20031001

• Pharmacologic treatment of Alzheimer's disease: an update.

  American family physician 20031001

• Modulation of MK-801-elicited mouse popping behavior by galantamine is complex and dose-dependent.

  Life sciences 20030919

• Efficacy and safety of cholinesterase inhibitors in Alzheimer's disease: a meta-analysis.

  CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne 20030916

• (-)-9-Dehydrogalanthaminium bromide, a new cholinesterase inhibitor, enhances place and object recognition memory in young and old rats.

  Neurobiology of learning and memory 20030901

• Treatment of Alzheimer's disease: current status and new perspectives.

  The Lancet. Neurology 20030901

• Update on Alzheimer drugs (galantamine).

  The neurologist 20030901

• Have cholinergic therapies reached their clinical boundary in Alzheimer's disease?

  International journal of geriatric psychiatry 20030901

• Combination pharmacotherapy in Alzheimer's disease.

  Dialogues in clinical neuroscience 20030901

• Nicotinic acetylcholine receptor-mediated neuroprotection by donepezil against glutamate neurotoxicity in rat cortical neurons.

  The Journal of pharmacology and experimental therapeutics 20030801

• Assessment of health economics in Alzheimer's disease (AHEAD): treatment with galantamine in the UK.

  International journal of geriatric psychiatry 20030801

• Alzheimer's disease: the pharmacological pathway.

  Fundamental & clinical pharmacology 20030801

• Sleep-related outcomes in persons with mild to moderate Alzheimer disease in a placebo-controlled trial of galantamine.

  Sleep 20030801

• Synthesis and structure-activity relationships of open D-Ring galanthamine analogues.

  Bioorganic & medicinal chemistry letters 20030721

• Protective effect of donepezil in a primary culture of rat cortical neurons exposed to oxygen-glucose deprivation.

  European journal of pharmacology 20030704

• [Acetylcholinesterase inhibitors].

  Revue medicale de la Suisse romande 20030701

• Development and validation of a liquid chromatographic-tandem mass spectrometric method for the determination of galantamine in human heparinised plasma.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20030615

• Galantamine is an allosterically potentiating ligand of neuronal nicotinic but not of muscarinic acetylcholine receptors.

  The Journal of pharmacology and experimental therapeutics 20030601

• An open-label extension trial of galantamine in patients with probable vascular dementia and mixed dementia.

  Clinical therapeutics 20030601

• Economic evaluation of galantamine in the treatment of mild to moderate Alzheimer's disease in the United States.

  Clinical therapeutics 20030601

• Plants used in Chinese and Indian traditional medicine for improvement of memory and cognitive function.

  Pharmacology, biochemistry, and behavior 20030601

• Dementia.

  Clinical evidence 20030601

• The impact of drugs against dementia on cognition in aging and mild cognitive impairment.

  Pharmacopsychiatry 20030601

• [Current therapy of patients with dementia].

  MMW Fortschritte der Medizin 20030526

• Synthesis, anticholinesterase activity and structure-activity relationships of m-Aminobenzoic acid derivatives.

  Bioorganic & medicinal chemistry letters 20030519

• Acetylcholine enhancement in the nucleus accumbens prevents addictive behaviors of cocaine and morphine.

  Proceedings of the National Academy of Sciences of the United States of America 20030513

• Extended lifetime of reagentless detector for multiple inhibitors of acetylcholinesterase.

  Biosensors & bioelectronics 20030501

• Galantamine population pharmacokinetics in patients with Alzheimer's disease: modeling and simulations.

  Journal of clinical pharmacology 20030501

• Galantamine.

  The Israel Medical Association journal : IMAJ 20030501

• The efficacy of galantamine in the treatment of Alzheimer's disease: comparison of patients previously treated with acetylcholinesterase inhibitors to patients with no prior exposure.

  International journal of geriatric psychiatry 20030401

• Increased sensitivity to agonist-induced seizures, straub tail, and hippocampal theta rhythm in knock-in mice carrying hypersensitive alpha 4 nicotinic receptors.

  The Journal of neuroscience : the official journal of the Society for Neuroscience 20030401

• Galantamine: a review of its use in Alzheimer's disease and vascular dementia.

  International journal of clinical practice 20030401

• Sequential designs for phase III clinical trials incorporating treatment selection.

  Statistics in medicine 20030315

• Galantamine hydrobromide: an agent for Alzheimer's disease.

  American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20030301

• Is the distinction between Alzheimer's disease and vascular dementia possible and relevant?

  Dialogues in clinical neuroscience 20030301

• The evaluation of cognitive function in the dementias: methodological and regulatory considerations.

  Dialogues in clinical neuroscience 20030301

• Treatment of cognitive impairment in Alzheimer's disease.

  Dialogues in clinical neuroscience 20030301

• Combined treatment with galanthaminium bromide, a new cholinesterase inhibitor, and RS 67333, a partial agonist of 5-HT4 receptors, enhances place and object recognition in young adult and old rats.

  Progress in neuro-psychopharmacology & biological psychiatry 20030201

• Acetylcholinesterase inhibitors for vascular dementia and Alzheimer's disease combined with cerebrovascular disease.

  Stroke 20030201

• Galantamine blocks delayed rectifier, but not transient outward potassium current in rat dissociated hippocampal pyramidal neurons.

  Neuroscience letters 20030109

• Patterns of clinically detectable treatment effects with galantamine: a qualitative analysis.

  Dementia and geriatric cognitive disorders 20030101

• Butyrylcholinesterase and acetylcholinesterase activity and quantal transmitter release at normal and acetylcholinesterase knockout mouse neuromuscular junctions.

  British journal of pharmacology 20030101

• Plants with traditional uses and activities, relevant to the management of Alzheimer's disease and other cognitive disorders.

  Phytotherapy research : PTR 20030101

• Galantamine provides sustained benefits in patients with 'advanced moderate' Alzheimer's disease for at least 12 months.

  Dementia and geriatric cognitive disorders 20030101

• Use of cholinesterase inhibitors in clinical practice: evidence-based recommendations.

  The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry 20030101

• Impact of study design and patient population on outcomes from cholinesterase inhibitor trials.

  The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry 20030101

• Mecamylamine interactions with galantamine and donepezil: effects on learning, acetylcholinesterase, and nicotinic acetylcholine receptors.

  Neuroscience 20030101

• Qualitative determination of false-positive effects in the acetylcholinesterase assay using thin layer chromatography.

  Phytochemical analysis : PCA 20030101

• Determining acetylcholinesterase inhibitory activity in plant extracts using a fluorimetric flow assay.

  Phytochemical analysis : PCA 20030101

• Inhibition of human cholinesterases by drugs used to treat Alzheimer disease.

  Alzheimer disease and associated disorders 20030101

• Ginkgo extract or cholinesterase inhibitors in patients with dementia: what clinical trials and guidelines fail to consider.

  Phytomedicine : international journal of phytotherapy and phytopharmacology 20030101

• Nicotinic receptors and Alzheimer's disease.

  Current medical research and opinion 20030101

• [Zoofilia as late complication of Parkinson's disease. Circe drugs and Mercury antidotes].

  Neurologia (Barcelona, Spain) 20030101

• Antioxidant properties of galantamine hydrobromide.

  Zeitschrift fur Naturforschung. C, Journal of biosciences 20030101

• A long-term comparison of galantamine and donepezil in the treatment of Alzheimer's disease.

  Drugs & aging 20030101

• Pharmacokinetics of galantamine, a cholinesterase inhibitor, in several animal species.

  Arzneimittel-Forschung 20030101

• Current treatments for Alzheimer's disease: cholinesterase inhibitors.

  The Journal of clinical psychiatry 20030101

• Galantamine in the treatment of cognitive decline in patients with vascular dementia or Alzheimer's disease with cerebrovascular disease.

  CNS drugs 20030101

• Galantamine demonstrates efficacy and safety in elderly patients with Alzheimer disease.

  Alzheimer disease and associated disorders 20030101

• Clinically significant drug interactions with cholinesterase inhibitors: a guide for neurologists.

  CNS drugs 20030101

• Potencies and selectivities of inhibitors of acetylcholinesterase and its molecular forms in normal and Alzheimer's disease brain.

  Acta biologica Hungarica 20030101

• Clinical experience of galantamine in dementia: a series of case reports.

  Current medical research and opinion 20030101

• Capillary electrophoresis as an orthogonal technique in HPLC method validation.

  Journal of capillary electrophoresis and microchip technology 20030101

• The pharmacist's role in managing patients with Alzheimer's disease.

  Journal of the American Pharmacists Association : JAPhA 20030101

• [Mechanisms of action of Alzheimer medications].

  Duodecim; laaketieteellinen aikakauskirja 20030101

• Galantamine vs donepezil in the treatment of Alzheimer's disease.

  Drugs & aging 20030101

• Clinical pharmacokinetics of galantamine.

  Clinical pharmacokinetics 20030101

• Rational choice of cholinesterase inhibitor for the treatment of Alzheimer's disease in Canada: a comparative economic analysis.

  BMC geriatrics 20030101

• [Galantamine (reminyl) in the treatment of Alzheimer's disease and vascular dementia].

  Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova 20030101

• Galantamine in the treatment of adult autism: a report of three clinical cases.

  International journal of psychiatry in medicine 20030101

• Galantamine in the treatment of vascular dementia.

  International psychogeriatrics 20030101

• Galantamine may be effective in treating autistic disorder.

  BMJ (Clinical research ed.) 20021214

• Enantioselective synthesis of (-)-codeine and (-)-morphine.

  Journal of the American Chemical Society 20021211

• [Early diagnosis and treatment of Alzheimer's disease. Implementation in the doctor's office].

  Fortschritte der Medizin. Originalien 20021205

• Unconventional ligands and modulators of nicotinic receptors.

  Journal of neurobiology 20021201

• Pharmacokinetic and safety assessments of galantamine and risperidone after the two drugs are administered alone and together.

  Journal of clinical pharmacology 20021201

• Treatment options: the latest evidence with galantamine (Reminyl).

  Journal of the neurological sciences 20021115

• The rationale behind cholinergic drug treatment for dementia related to cerebrovascular disease.

  Journal of the neurological sciences 20021115

• Use of galantamine to treat vascular dementia.

  Lancet (London, England) 20021109

• Use of galantamine to treat vascular dementia.

  Lancet (London, England) 20021109

• Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomized trial.

  Current neurology and neuroscience reports 20021101

• [Treatment of Alzheimer's disease].

  Revista de neurologia 20021101

• [Rivastigmine: a review of its clinical effectiveness].

  Revista de neurologia 20021101

• Progress in clinical neurosciences: Treatment of Alzheimer's disease and other dementias--review and comparison of the cholinesterase inhibitors.

  The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques 20021101

• A novel treatment for patients with Alzheimer's disease and with vascular dementia.

  Annals of the New York Academy of Sciences 20021101

• Broad therapeutic benefits in patients with probable vascular dementia or Alzheimer's disease with cerebrovascular disease treated with galantamine.

  Annals of the New York Academy of Sciences 20021101

• [Anti-dementia drugs for Alzheimer disease in present and future].

  Nihon yakurigaku zasshi. Folia pharmacologica Japonica 20021101

• A nitric oxide-donating flurbiprofen derivative reduces neuroinflammation without interacting with galantamine in the rat.

  European journal of pharmacology 20021025

• Acetylcholinesterase inhibitory activity of some Amaryllidaceae alkaloids and Narcissus extracts.

  Life sciences 20021011

• The impact of journal advertisements on prescribers of cholinesterase inhibitors.

  International journal of geriatric psychiatry 20021001

• [Galantamine: a novel cholinergic agent for Alzheimer's disease].

  Neurologia (Barcelona, Spain) 20021001

• Bioactive constituents from Iryanthera megistophylla.

  Journal of natural products 20021001

• Cognitive pharmacotherapy of Alzheimer's disease and other dementias.

  Canadian journal of psychiatry. Revue canadienne de psychiatrie 20021001

• [The role of substantia nigra in the cognitive activity in cats].

  Rossiiskii fiziologicheskii zhurnal imeni I.M. Sechenova 20021001

• Quaternary salts of E2020 analogues as acetylcholinesterase inhibitors for the reversal of neuromuscular block.

  Bioorganic & medicinal chemistry letters 20020916

• Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomized trial.

  Current neurology and neuroscience reports 20020901

• Galantamine pharmacokinetics, safety, and tolerability profiles are similar in healthy Caucasian and Japanese subjects.

  Journal of clinical pharmacology 20020901

• Broad therapeutic benefits in patients with probable vascular dementia or Alzheimer's disease with cerebrovascular disease after treatment with galantamine.

  European journal of neurology 20020901

• Galantamine provides broad benefits in patients with 'advanced moderate' Alzheimer's disease (MMSE < or = 12) for up to six months.

  International journal of clinical practice 20020901

• Cerebrospinal fluid levels of biomarkers and activity of acetylcholinesterase (AChE) and butyrylcholinesterase in AD patients before and after treatment with different AChE inhibitors.

  Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology 20020901

• Anticholinesterase activity of compounds related to geneserine tautomers. N-Oxides and 1,2-oxazines.

  Journal of medicinal chemistry 20020815

• An efficient enantioselective synthesis of (-)-galanthamine.

  Angewandte Chemie (International ed. in English) 20020802

• Galantamine for vascular dementia.

  The Lancet. Neurology 20020801

• Galantamine for treatment-resistant schizophrenia.

  The American journal of psychiatry 20020701

• Medical treatment of Alzheimer's disease: past, present, and future.

  Medicine and health, Rhode Island 20020701

• [Nicotinic Receptor, galantamine and Alzheimer disease].

  Revista de neurologia 20020601

• The efficacy of cholinesterase inhibitors in treating the behavioural symptoms of dementia.

  International journal of clinical practice. Supplement 20020601

• The tolerability and safety of cholinesterase inhibitors in the treatment of dementia.

  International journal of clinical practice. Supplement 20020601

• Evidence that the clinical effects of cholinesterase inhibitors are related to potency and targeting of action.

  International journal of clinical practice. Supplement 20020601

• Switching cholinesterase inhibitors in patients with Alzheimer's disease.

  International journal of clinical practice. Supplement 20020601

• Galanthamine as bis-functional ligand for the acetylcholinesterase.

  Journal of molecular modeling 20020601

• [Latest therapies for treating dementia].

  Atencion primaria 20020515

• [Dementing disorders. What benefits do the new anti-dementia drugs have?].

  MMW Fortschritte der Medizin 20020506

• The metabolism and excretion of galantamine in rats, dogs, and humans.

  Drug metabolism and disposition: the biological fate of chemicals 20020501

• The nicotinic allosteric potentiating ligand galantamine facilitates synaptic transmission in the mammalian central nervous system.

  Molecular pharmacology 20020501

• Pharmacologic treatments of dementia.

  The Medical clinics of North America 20020501

• Galantamine for vascular dementia: some answers, some questions.

  Lancet (London, England) 20020413

• Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomised trial.

  Lancet (London, England) 20020413

• Pharmacokinetics and safety of galantamine in subjects with hepatic impairment and healthy volunteers.

  Journal of clinical pharmacology 20020401

• Pd asymmetric allylic alkylation (AAA). A powerful synthetic tool.

  Chemical & pharmaceutical bulletin 20020101

• A rapid TLC bioautographic method for the detection of acetylcholinesterase and butyrylcholinesterase inhibitors in plants.

  Phytochemical analysis : PCA 20020101

• A non-cholinergic, trophic action of acetylcholinesterase on hippocampal neurones in vitro: molecular mechanisms.

  Neuroscience 20020101

• Understanding and managing behavioural symptoms in Alzheimer's disease and related dementias: focus on rivastigmine.

  Current medical research and opinion 20020101

• Cholinergic medication for neuroleptic-induced tardive dyskinesia.

  The Cochrane database of systematic reviews 20020101

• Galantamine for Alzheimer's disease.

  The Cochrane database of systematic reviews 20020101

• Assessment of Health Economics in Alzheimer's Disease (AHEAD): treatment with galantamine in Sweden.

  PharmacoEconomics 20020101

• Economic analysis of galantamine, a cholinesterase inhibitor, in the treatment of patients with mild to moderate Alzheimer's disease in the Netherlands.

  Dementia and geriatric cognitive disorders 20020101

• [New theory! Galantamine and nicotinic-cholinergic transmission].

  Pharmazie in unserer Zeit 20020101

• Clinical pharmacokinetics and pharmacodynamics of cholinesterase inhibitors.

  Clinical pharmacokinetics 20020101

• Galantamine--a novel cholinergic drug with a unique dual mode of action for the treatment of patients with Alzheimer's disease.

  CNS drug reviews 20020101

• To what degree does cognitive impairment in Alzheimer's disease predict dependence of patients on caregivers?

  BMC neurology 20020101

• New drugs 2002, part 1.

  Nursing 20020101

• Galantamine: a pharmacoeconomic review of its use in Alzheimer's disease.

  PharmacoEconomics 20020101

• Clinical and cost-effectiveness of donepezil, rivastigmine, and galantamine for Alzheimer's disease. A systematic review.

  International journal of technology assessment in health care 20020101

• Adjuvant galantamine administration improves negative symptoms in a patient with treatment-refractory schizophrenia.

  Clinical neuropharmacology 20020101

• Galantamine improved cognition and global functioning in vascular dementia or Alzheimer disease with cerebrovascular disease.

  ACP journal club 20020101

• The cholinergic approach for the treatment of vascular dementia: evidence from pre-clinical and clinical studies.

  Clinical and experimental hypertension (New York, N.Y. : 1993) 20020101

• Nicotinic receptor modulation: advantages for successful Alzheimer's disease therapy.

  Journal of neural transmission. Supplementum 20020101

• Nicotinic cholinergic modulation: galantamine as a prototype.

  CNS drug reviews 20020101

• Vascular dementia: galantamine (Reminyl) as an emerging therapeutic option.

  Acta neurologica Scandinavica. Supplementum 20020101

• Cognitive decline and treatment options for patients with vascular dementia.

  Acta neurologica Scandinavica. Supplementum 20020101

• Non-cognitive benefits of galantamine (Reminyl) treatment in vascular dementia.

  Acta neurologica Scandinavica. Supplementum 20020101

• Solid-phase extraction and reversed-phase high-performance liquid chromatography of the five major alkaloids in Narcissus confusus.

  Phytochemical analysis : PCA 20020101

• The ABC of Alzheimer's disease: ADL and improving day-to-day functioning of patients.

  International psychogeriatrics 20020101

• The ABC of Alzheimer's disease: behavioral symptoms and their treatment.

  International psychogeriatrics 20020101

• A clinical overview of cholinesterase inhibitors in Alzheimer's disease.

  International psychogeriatrics 20020101

• [Acetylcholinesterase inhibitors--beyond Alzheimer's disease].

  Psychiatria polska 20020101

• [Alzheimer dementia. Comparison of the effectiveness of cholinesterase inhibitors and gingko].

  MMW Fortschritte der Medizin 20011213

• Unsafe prescription medication switching recommendations.

  Clinical therapeutics 20011201

• Galantamine: new preparation. The fourth cholinesterase inhibitor for Alzheimer's disease.

  Prescrire international 20011201

• Current status and new developments with galantamine in the treatment of Alzheimer's disease.

  Expert opinion on pharmacotherapy 20011201

• [Perspectives for drug treatment in Alzheimer's disease].

  Annales de medecine interne 20011201

• Galantamine hydrobromide.

  American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20011115

• Effects of a flexible galantamine dose in Alzheimer's disease: a randomised, controlled trial.

  Journal of neurology, neurosurgery, and psychiatry 20011101

• Galantamine: a new alzheimer drug with a past life.

  The Annals of pharmacotherapy 20011101

• Galantamine: a new treatment for Alzheimer's disease.

  Expert review of neurotherapeutics 20011101

• Assessment of health economics in Alzheimer's disease (AHEAD): galantamine treatment in Canada.

  Neurology 20010925

• Sleep and the cholinergic rapid eye movement sleep induction test in patients with primary alcohol dependence.

  Biological psychiatry 20010901

• Galantamine: a randomized, double-blind, dose comparison in patients with Alzheimer's disease.

  International journal of geriatric psychiatry 20010901

• [Anticholinesterase agents in Alzheimer's disease].

  Revue medicale de Bruxelles 20010901

• Use of acetylcholinesterase inhibitors in Alzheimer's disease.

  Expert review of neurotherapeutics 20010901

• Therapeutic approaches to age-associated neurocognitive disorders.

  Dialogues in clinical neuroscience 20010901

• Medications for the treatment of Alzheimer's disease.

  The Journal of the Oklahoma State Medical Association 20010801

• Modulation of nicotinic receptor activity in the central nervous system: a novel approach to the treatment of Alzheimer disease.

  Alzheimer disease and associated disorders 20010801

• Maintaining cognitive function in Alzheimer disease: how effective are current treatments?

  Alzheimer disease and associated disorders 20010801

• Maintaining functional and behavioral abilities in Alzheimer disease.

  Alzheimer disease and associated disorders 20010801

• Use of biomimetic diversity-oriented synthesis to discover galanthamine-like molecules with biological properties beyond those of the natural product.

  Journal of the American Chemical Society 20010711

• Use of cholinesterase inhibitors for treatment of Alzheimer disease.

  Cleveland Clinic journal of medicine 20010701

• Featured CME topic: dementia. Medication update.

  Southern medical journal 20010701

• Galantamine (reminyl) for Alzheimer's disease.

  The Medical letter on drugs and therapeutics 20010625

• Alzheimer's disease and related disorders.

  The Medical clinics of North America 20010501

• Meeting the challenges of vascular dementia. Introduction.

  International journal of clinical practice. Supplement 20010501

• The pharmacological rationale for treating vascular dementia with galantamine (Reminyl).

  International journal of clinical practice. Supplement 20010501

• Screening for acetylcholinesterase inhibitors from Amaryllidaceae using silica gel thin-layer chromatography in combination with bioactivity staining.

  Journal of chromatography. A 20010427

• FDA approves galantamine for Alzheimer's disease.

  American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20010415

• Muscarinic agonists and antagonists in the treatment of Alzheimer's disease.

  Farmaco (Societa chimica italiana : 1989) 20010401

• Differential increase in cerebrospinal fluid-acetylcholinesterase after treatment with acetylcholinesterase inhibitors in patients with Alzheimer's disease.

  Neuroscience letters 20010316

• Galantamine: effect on nicotinic receptor binding, acetylcholinesterase inhibition, and learning.

  Proceedings of the National Academy of Sciences of the United States of America 20010213

• Three-dimensional structure of a complex of galanthamine (Nivalin) with acetylcholinesterase from Torpedo californica: implications for the design of new anti-Alzheimer drugs.

  Proteins 20010201

• Allosteric sensitization of nicotinic receptors by galantamine, a new treatment strategy for Alzheimer's disease.

  Biological psychiatry 20010201

• Galantamine, a cholinesterase inhibitor that allosterically modulates nicotinic receptors: effects on the course of Alzheimer's disease.

  Biological psychiatry 20010201

• APOE genotype: no influence on galantamine treatment efficacy nor on rate of decline in Alzheimer's disease.

  Dementia and geriatric cognitive disorders 20010101

• Cholinesterase inhibitors for Alzheimer's disease.

  Drugs 20010101

• Clinical and cost-effectiveness of donepezil, rivastigmine and galantamine for Alzheimer's disease: a rapid and systematic review.

  Health technology assessment (Winchester, England) 20010101

• Galantamine for Alzheimer's disease.

  The Cochrane database of systematic reviews 20010101

• Therapeutic continuity in Alzheimer's disease: switching patients to galantamine. Introduction.

  Clinical therapeutics 20010101

• Pharmacokinetic profiles of current therapies for Alzheimer's disease: implications for switching to galantamine.

  Clinical therapeutics 20010101

• Effects of washout and dose-escalation periods on the efficacy, safety, and tolerability of galantamine in patients previously treated with donepezil: ongoing clinical trials.

  Clinical therapeutics 20010101

• Switching previous therapies for Alzheimer's disease to galantamine.

  Clinical therapeutics 20010101

• Therapeutic continuity in Alzheimer's disease: switching patients to galantamine. Panel discussion: recommendations for prescribers.

  Clinical therapeutics 20010101

• Pharmacokinetic rationale for switching from donepezil to galantamine.

  Clinical therapeutics 20010101

• Galantamine introduced in Europe.

  American journal of Alzheimer's disease and other dementias 20010101

• Accurate prediction of the bound conformation of galanthamine in the active site of Torpedo californica acetylcholinesterase using molecular docking.

  Journal of molecular graphics & modelling 20010101

• Newest developments in dementia treatment and prevention.

  Geriatric nursing (New York, N.Y.) 20010101

• Galantamine for Alzheimer's disease.

  The Cochrane database of systematic reviews 20010101

• Drugs used for cognitive symptoms of Alzheimer's disease.

  Perspectives in psychiatric care 20010101

• Galantamine: a review of its use in Alzheimer's disease.

  Drugs 20001101

• Structure of acetylcholinesterase complexed with (-)-galanthamine at 2.3 A resolution.

  FEBS letters 19991217

• [The selectivity of the action of muscarinic agonists in vivo].

  Eksperimental'naia i klinicheskaia farmakologiia 19940101

• Effects of four non-cholinergic cognitive enhancers in comparison with tacrine and galanthamine on scopolamine-induced amnesia in rats.

  Psychopharmacology 19920101

• Galanthamine hydrobromide, a longer acting anticholinesterase drug, in the treatment of the central effects of scopolamine (Hyoscine).

  Der Anaesthesist 19771201